[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 850
1. Mao TL, Hsu CY, Yen MJ, Gilks B, Sheu JJ, Gabrielson E, Vang R, Cope L, Kurman RJ, Wang TL, Shih IeM: Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol; 2006 Sep;37(9):1169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma.
  • Our previous study showed that Rsf-1 was an amplified gene that participated in the development of ovarian serous carcinoma.
  • Rsf-1 overexpression was observed in 25% of high-grade ovarian serous carcinomas and in only rare cases (<7%) of low-grade ovarian serous, ovarian endometrioid, and invasive breast carcinomas but not in any ovarian serous borderline tumors, ovarian clear cell carcinomas, ovarian mucinous carcinomas, intraductal carcinomas of the breast, and normal ovaries and breast tissues.
  • Thus, overexpression of Rsf-1 was significantly associated with high-grade ovarian serous carcinoma (P < .05), as compared with other types of ovarian tumors and breast carcinomas.
  • Our results provide evidence that Rsf-1 expression is primarily confined to high-grade serous carcinoma, the most aggressive ovarian cancer.
  • Because Rsf-1 overexpression occurs in only a small number of breast carcinomas, it is unlikely that Rsf-1 is a critical gene in the development of breast carcinoma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938522.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103937-03; United States / NCI NIH HHS / CA / R01 CA103937; United States / NCI NIH HHS / CA / CA103937; United States / NCI NIH HHS / CA / R01 CA103937-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / RSF1 protein, human; 0 / Trans-Activators
  •  go-up   go-down


2. Rabban JT, Koerner FC, Lerwill MF: Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Hum Pathol; 2006 Jul;37(7):787-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
  • The solid papillary variant of ductal carcinoma in situ is an uncommon entity, which usually presents in the seventh or eighth decade and may be associated with invasive mucinous carcinoma.
  • Solid papillary ductal carcinoma in situ (SP-DCIS) shares many morphological features with usual ductal hyperplasia (UDH) involving a papilloma: papillary architecture, solid growth, cellular streaming, and low-grade nuclear features.
  • Recent studies have demonstrated that immunohistochemical staining for cytokeratin 5/6 can distinguish UDH from conventional forms of ductal carcinoma in situ.
  • Most of the epithelial cells of UDH express cytokeratin 5/6, but the tumor cells of ductal carcinoma in situ do not.
  • We tested the hypothesis that the results of staining for cytokeratin 5/6 can distinguish UDH from the solid papillary variant of ductal carcinoma in situ.
  • Pathologists must guard against misinterpreting SP-DCIS as UDH in those cases in which the carcinoma cells engulf cytokeratin 5/6-expressing residual, native epithelial cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Papillary / diagnosis. Keratins / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Immunohistochemistry. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784976.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


3. Borzomati D, Valeri S, Grasso F, Rabitti C, Vitolo D, Santini D, Vincenzi B, Garberini A, La Vaccara V, Coppola R: Pancreatic intraductal papillary mucinous neoplasms: a paradigmatic case. A case report and review of the literature. Chir Ital; 2008 Jul-Aug;60(4):567-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraductal papillary mucinous neoplasms: a paradigmatic case. A case report and review of the literature.
  • Pancreatic intraductal papillary mucinous neoplasms constitute an increasingly frequent clinical entity.
  • As a consequence, their clinical management is also presents controversial aspects ranging from follow-up to the advisability or otherwise of an aggressive surgical approach, even in the case of small non-malignant lesions.
  • In 2002 we observed a patient affected by a large pancreatic mass with the endoscopic and radiological features of an intraductal papillary mucinous tumour.
  • Total pancreatectomy was performed and final histology revealed a non-invasive papillary mucinous carcinoma of the pancreas.
  • Twenty-six months after surgical resection the patient is alive and free of disease.
  • [MeSH-major] Adenocarcinoma, Mucinous. Neoplasms, Multiple Primary. Pancreatic Neoplasms. Papilloma, Intraductal
  • [MeSH-minor] Diagnostic Errors. Humans. Male. Middle Aged. Pancreatitis / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837259.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 40
  •  go-up   go-down


Advertisement
4. Linda A, Zuiani C, Girometti R, Londero V, Machin P, Brondani G, Bazzocchi M: Unusual malignant tumors of the breast: MRI features and pathologic correlation. Eur J Radiol; 2010 Aug;75(2):178-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual malignant tumors of the breast: MRI features and pathologic correlation.
  • Unusual malignant breast tumors are well-differentiated subtypes of invasive ductal carcinoma, including mucinous, tubular, medullary and papillary carcinomas, and account for about 10% of malignant breast tumors.
  • This review provides an overview of MRI characteristics of a range of unusual tumors (mucinous carcinoma, medullary carcinoma, tubular carcinoma, intraductal papillary carcinoma, intracystic papillary carcinoma and invasive papillary carcinoma), highlighting specific clues for diagnosis and correlating MRI and pathologic features.
  • Nevertheless, an understanding of pathologic features of these tumors, especially tissue content (mucinous, fibrous) and growth pattern, can help to define some specific clues for their diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast / pathology. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / pathology. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19446418.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


5. Ibáñez Aguirre FJ, Erro Azcárate JM, Aranda Lozano F, Almendral López ML, Valentí Ponsa C, Echenique Elizondo M: [Mucinous adenocarcinoma on chronic perianal fistula treated by neoadjuvant QT-RT neoadyuvante and laparoscopic abdomino-perineal resection]. Rev Esp Enferm Dig; 2006 Apr;98(4):310-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous adenocarcinoma on chronic perianal fistula treated by neoadjuvant QT-RT neoadyuvante and laparoscopic abdomino-perineal resection].
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Adenocarcinoma, Mucinous / therapy. Anus Neoplasms / complications. Anus Neoplasms / therapy. Laparoscopy. Rectal Fistula / complications

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16792461.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


6. Buyukcelik A, Bulent Y, Utkan G, Icli F, Sanlidilek U, Akbulut H: Thrombosis of the pulmonary artery in a patient with mucinous adenocarcinoma. Med Sci Monit; 2006 Sep;12(9):CS90-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombosis of the pulmonary artery in a patient with mucinous adenocarcinoma.
  • These findings suggested that the thrombosis in the right pulmonary artery was primary rather than an embolus.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Peritoneal Neoplasms / complications. Pulmonary Embolism / radiography

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940937.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


7. Akiyama F, Horii R: Therapeutic strategies for breast cancer based on histological type. Breast Cancer; 2009;16(3):168-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is generally accepted that the histological types of breast cancer are clinically significant because they serve as prognosticators and as the common language for improving the accuracy of clinical diagnosis.
  • It is necessary to diagnose breast cancer at the level of not only histological findings by needle biopsy, but also the histologic type based on diagnostic imaging and cytological diagnosis.
  • Preoperative drug therapy can be planned by making a histological diagnosis based on needle biopsy findings.
  • Preoperative drug therapy is not indicated for noninvasive carcinoma and papillotubular carcinoma (invasive carcinoma with predominant intraductal components).
  • While complete loss of interstitial infiltration can be expected with solid-tubular carcinoma, it cannot be expected with other histological types, such as invasive lobular carcinoma, adenoid cystic carcinoma, or metaplastic carcinoma (squamous-cell carcinoma and spindle-cell carcinoma).
  • On therapeutic response assessment, the clinical and pathological findings generally match for solid-tubular carcinoma but not for scirrhous carcinoma and invasive lobular carcinoma.
  • With mucinous carcinoma, mucus accumulation can remain, even though most cancer cells disappear; as a result, assessment based on tumor diameter changes is difficult.
  • Histological diagnosis is also significant from the viewpoint of drug sensitivity, and it is important to maintain the accuracy of histological diagnosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma / drug therapy


8. Ishioka S, Hayashi T, Endo T, Baba T, Honma H, Saito T: Advanced epithelial ovarian carcinoma during pregnancy. Int J Clin Oncol; 2007 Oct;12(5):375-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced epithelial ovarian carcinoma during pregnancy.
  • We report a rare case of advanced ovarian mucinous adenocarcinoma in a pregnant woman.
  • Advanced ovarian carcinoma with widespread intraabdominal dissemination was detected by laparotomy at the hospital and she was referred to our hospital for further management.
  • The pathological diagnosis of the tumor was mucinous cystadenocarcinoma grade 2.
  • Although chemotherapy was not effective for her and she died of the disease 4 months after the surgery, her baby grew well and weighed 3750 g 3 months after delivery.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Dec;27(6):686-98 [11130476.001]
  • [Cites] Am J Obstet Gynecol. 1984 Jun 15;149(4):384-7 [6731515.001]
  • [Cites] Am J Obstet Gynecol. 1989 Mar;160(3):563-6 [2929674.001]
  • [Cites] Acta Paediatr. 2004 Jul;93(7):945-53 [15303811.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):600-4 [15297214.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):78-80 [2026364.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1120-3 [16343192.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):8-15 [16445603.001]
  • [Cites] J Nippon Med Sch. 2002 Feb;69(1):39-42 [11847508.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):545-7 [2304734.001]
  • (PMID = 17929120.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Kirkpatrick ID, Desser TS, Nino-Murcia M, Jeffrey RB: Small cystic lesions of the pancreas: clinical significance and findings at follow-up. Abdom Imaging; 2007 Jan-Feb;32(1):119-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Lesions with pathologic correlation proved to be: side branch intraductal papillary mucinous neoplasm or tumor (IPMT) (n = 5), combined type IPMT (n = 4), nonmucinous cyst (n = 4), chronic pancreatitis (n = 2), and reactive atypia with nonmucinous fluid (n = 1), combined type IMPT with foci of adenocarcinoma (n = 1), mucinous adenocarcinoma (n = 2), and nonmucinous adenocarcinoma (n = 1).
  • Lesions with solid components were significantly more likely to grow and be malignant (P < 0.05).
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma, Mucinous / radiography. Adenocarcinoma, Papillary / radiography. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Dilatation, Pathologic / radiography. Disease Progression. Female. Follow-Up Studies. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Pancreatic Ducts / radiography. Pancreatitis, Chronic / radiography. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944031.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Park JH, Whang SO, Song ES, Choi SJ, Lee WY: An ovarian mucinous cystadenocarcinoma arising from mature cystic teratoma with para-aortic lymph node metastasis: a case report. J Gynecol Oncol; 2008 Dec;19(4):275-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An ovarian mucinous cystadenocarcinoma arising from mature cystic teratoma with para-aortic lymph node metastasis: a case report.
  • Malignant transformation of a mature cystic teratoma (MCT) is an uncommon complication.
  • The most common form of malignant transformation of a MCT is squamous cell carcinoma, representing 75% of malignant transformations.
  • The frequency of malignant transformation of MCT to adenocarcinoma is just 6.8%.
  • To the best of our knowledge, no case of para-aortic lymph node metastasis in mucinous adenocarcinoma arising from MCT has been reported before.
  • The prognosis of malignant transformation of the MCT is very poor.
  • Here, we report an unusual case of a 41-year-old woman with mucinous adenocarcinoma arising from MCT with para-aortic lymph node metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:60-7 [16515569.001]
  • [Cites] Gynecol Oncol. 1998 Sep;70(3):418-20 [9790798.001]
  • [Cites] J Clin Pathol. 1996 Jun;49(6):519-21 [8763274.001]
  • [Cites] Gynecol Oncol. 1995 Dec;59(3):427-9 [8522269.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):97-101 [7821857.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):259-63 [8381377.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):131-3 [8349156.001]
  • [Cites] Gynecol Oncol. 1988 Feb;29(2):250-4 [3338676.001]
  • [Cites] Am J Obstet Gynecol. 1980 Dec 15;138(8):1120-3 [7446619.001]
  • [Cites] Br J Obstet Gynaecol. 1979 May;86(5):399-402 [465388.001]
  • [Cites] Cancer. 1977 Mar;39(3):1237-42 [912656.001]
  • [Cites] Ann Clin Lab Sci. 2003 Fall;33(4):465-70 [14584762.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1447-64 [11075847.001]
  • [Cites] Pathology. 2006 Dec;38(6):534-8 [17393980.001]
  • (PMID = 19471656.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676486
  • [Keywords] NOTNLM ; Mature cystic teratoma / Mucinous cystadenocarcinoma / Para-aortic lymph node
  •  go-up   go-down


11. Del Casar JM, González-Reyes S, González LO, González JM, Junquera S, Bongera M, García MF, Andicoechea A, Serra C, Vizoso FJ: Expression of metalloproteases and their inhibitors in different histological types of breast cancer. J Cancer Res Clin Oncol; 2010 Jun;136(6):811-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: An immunohistochemical study was performed in 50 ductal, 23 lobular, 14 mucinous, 7 tubular, 4 papillary and 5 medullary invasive carcinomas, using tissue arrays and specific antibodies against 7 MMPs and 3 tisullar TIMPs.
  • RESULTS: Carcinomas of the ductal type showed higher score values for MMPs and TIMPs than the other histological types; whereas mucinous carcinomas had lower scores values for expressions of the majority of these proteins.
  • Stromal fibroblasts were more frequently positive for MMP-1, -7 and -13 and TIMP-1 and -3, when present in carcinomas of the ductal type than in other histological types of breast carcinomas.
  • Stromal mononuclear inflammatory cells were more frequently positive for MMP-1 and TIMP-3, but more often negative for MMP-7, -9 and -11, when located in carcinomas of the ductal type than in other histological types of breast carcinomas.
  • CONCLUSIONS: We found variations in MMP/TIMP expressions among the different histological subtypes of breast carcinomas suggesting differences in their tumor pathophysiology.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Tissue Array Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):215-27 [15947098.001]
  • [Cites] Cancer. 2001 Apr 15;91(8 Suppl):1679-87 [11309768.001]
  • [Cites] Histopathology. 2003 Jan;42(1):37-42 [12493023.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 1):111-118 [11112695.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):113-20 [8630916.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1544-50 [8576151.001]
  • [Cites] J Pathol. 1998 Mar;184(3):265-71 [9614378.001]
  • [Cites] Science. 2002 May 10;296(5570):1046-9 [12004111.001]
  • [Cites] Cell. 1997 Mar 21;88(6):801-10 [9118223.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):147-53 [8380113.001]
  • [Cites] Breast Cancer Res Treat. 1992;22(3):207-19 [1391987.001]
  • [Cites] Breast Cancer Res Treat. 2004 May;85(1):23-9 [15039595.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1046-52 [16175185.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):3-10 [12086880.001]
  • [Cites] Eur J Surg Oncol. 1991 Jun;17 (3):251-7 [1646127.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14 ):5454-9 [16569699.001]
  • [Cites] Neoplasia. 2001 Nov-Dec;3(6):459-68 [11774028.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):957-63 [17848954.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):247-51 [11119712.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2289-98 [15073104.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1270-5 [14520459.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):723-8 [12090420.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):903-11 [17342087.001]
  • [Cites] J Clin Epidemiol. 1997 Mar;50(3):283-90 [9120527.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1196-201 [14652000.001]
  • [Cites] J Pathol. 1999 Oct;189(2):161-8 [10547569.001]
  • [Cites] Histopathology. 2008 Oct;53(4):403-15 [18983606.001]
  • [Cites] Pol J Pathol. 1995;46(1):11-5 [7780691.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6012-9 [16115946.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1459-64 [8608529.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):804-13 [10679650.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6845-52 [9862716.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1105-11 [12402149.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):6935-45 [10066747.001]
  • [Cites] J Am Coll Surg. 1998 Apr;186(4):416-22 [9544955.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1566-72 [18503039.001]
  • [Cites] Cancer Cell. 2004 May;5(5):409-10 [15144947.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1237-41 [10225966.001]
  • [Cites] Semin Cancer Biol. 2005 Apr;15(2):149-57 [15652460.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1347-55 [10188875.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1792-7 [7880608.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):634-5 [1850613.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):782-9 [10741697.001]
  • [Cites] Breast Cancer Res. 2000;2(4):252-7 [11250717.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1207-12 [12698185.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7091-100 [11585740.001]
  • [Cites] ANZ J Surg. 2001 Jan;71(1):27-31 [11167594.001]
  • [Cites] APMIS. 1999 Jan;107(1):80-5 [10190283.001]
  • (PMID = 19916023.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.- / Metalloproteases
  •  go-up   go-down


12. Matei MC, Căruntu ID, Negură L, Petrariu FD, Ifrim S, Acatrinei L, Sulugiuc A, Azoicăi D: The assessment of relations between main histologic type of ovarian cancer and some risk and prognostic factors. Rev Med Chir Soc Med Nat Iasi; 2010 Oct-Dec;114(4):1135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The assessment of age group distribution of patients with serous carcinoma (150 cases) underlying that the age group of 60-69 years was more frequent compared with the other age groups (OR = 0.20; IC 95% = 0.12-0.33; p < 0.01 x 10(-5)) and the mean of age was 61 years, 8 months, 19 days (DS = 11 years, 11 months, 22 days).
  • The most frequent risk factor for serous type was the ovulation lifetime over 30 years (78.66%); followed by early menarche (under 12 years) (13.33%); smoking (12%); late menopause (over 52 years) (10%) and hormone replacement therapy (HRT) (2.67%), compared with mucinous carcinoma for which the most frequent was the ovulation lifetime over 30 years (65.21%); followed by early menarche (under 12 years) (34.78%); late menopause (over 52 years) (26.08%) and smoking (17.39%).
  • Smoking was more frequent among those who had mucinous carcinoma compared with serous type.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495458.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  •  go-up   go-down


13. Svrcek M, Cosnes J, Beaugerie L, Parc R, Bennis M, Tiret E, Fléjou JF: Colorectal neoplasia in Crohn's colitis: a retrospective comparative study with ulcerative colitis. Histopathology; 2007 Apr;50(5):574-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To determine the clinicopathological features of colorectal cancer (CRC) in Crohn's disease (CD).
  • METHODS AND RESULTS: All histological slides from surgical specimens with inflammatory bowel disease-related colorectal neoplasia examined in our hospital between 1990 and 2005 were reviewed.
  • When CD and UC were compared, the median age at diagnosis of cancer (CD 52 years, UC 51 years), the frequency of mucinous adenocarcinoma (CD 16.7%, UC 17.5%) and the frequency of dysplasia adjacent to and distal from cancer (CD 56.3 and 37.5%, UC 65.8 and 39%, respectively) were similar.
  • All neoplastic lesions occurred in areas affected by inflammatory bowel disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colitis / pathology. Colorectal Neoplasms / pathology. Crohn Disease / pathology. Precancerous Conditions / pathology


14. Tajiri T, Tate G, Inagaki T, Kunimura T, Inoue K, Mitsuya T, Yoshiba M, Morohoshi T: Intraductal tubular neoplasms of the pancreas: histogenesis and differentiation. Pancreas; 2005 Mar;30(2):115-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Intraductal neoplasms of the pancreas are generally referred to as intraductal papillary mucin-producing neoplasms (IPMNs), according to the WHO classification system.
  • Herein, we report that morphologic and immunohistochemical features of intraductal tubular carcinoma (ITC) are quite different from those of intraductal papillary mucinous carcinoma (IPMC).
  • RESULTS: Histologically, ITC was characterized as an intraductal nodular appearances with a monotonous tubular growth pattern without papillary projection.
  • ITC showed de novo-like appearance without sequential progression usually observed in IPMC, suggesting that ITC is a homogeneous neoplasm.
  • In contrast to ITC cells, IPMC cells were negative for MUC-1, and ductal adenocarcinoma cells were strongly positive for MUC-1, as was the stroma around the cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Renal Cell / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714133.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


15. Mikami Y, Kiyokawa T, Sasajima Y, Teramoto N, Wakasa T, Wakasa K, Hata S: Reappraisal of synchronous and multifocal mucinous lesions of the female genital tract: a close association with gastric metaplasia. Histopathology; 2009 Jan;54(2):184-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reappraisal of synchronous and multifocal mucinous lesions of the female genital tract: a close association with gastric metaplasia.
  • AIMS: To describe the gastric phenotype of synchronous mucinous metaplasia and neoplasms of the female genital tract (SMMN-FGT).
  • All six patients had mucinous metaplasia of endometrium, which showed features of lobular endocervical glandular hyperplasia (LEGH)/pyloric gland metaplasia (PGM) in five and was associated with mucinous adenocarcinoma in three.
  • Five patients had mucinous metaplasia of the fallopian tubes, of which three showed borderline features.
  • Two patients had mucinous borderline tumour of the ovary.
  • Five patients had cervical lesions including LEGH/PGM associated with either adenocarcinoma in situ or minimal deviation adenocarcinoma of the cervix.
  • All mucinous lesions were positive for HIK1083 and/or MUC6.
  • One patient with minimal deviation adenocarcinoma involving the vagina died of her disease, whereas five patients, including three with microinvasion and three with positive peritoneal cytology or mucinous ascites, were alive without recurrence after a mean follow-up of 46 months (range 13-102 months).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cervix Uteri / pathology. Gastric Mucosa / pathology. Genital Neoplasms, Female / pathology. Neoplasms, Multiple Primary / pathology

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207943.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Mizuta Y, Akazawa Y, Shiozawa K, Ohara H, Ohba K, Ohnita K, Isomoto H, Takeshima F, Omagari K, Tanaka K, Yasutake T, Nakagoe T, Shirono K, Kohno S: Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas. Pancreatology; 2005;5(4-5):470-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas.
  • We describe a case of pseudomyxoma peritonei (PMP) successfully managed with intraperitoneal hyperthermic chemoperfusion.
  • This case is unique due to the concurrent presence of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • Cytological examination of ascitic fluid sample showed mucin-rich atypical cells.
  • Endoscopic retrograde pancreatography revealed a cystic lesion with the defect probably due to mural nodule and mucin, communicating with the pancreatic duct.
  • No primary tumour, including mucinous neoplasm of the appendix, was found.
  • Histopathological examination of the omentum showed mucinous adenocarcinoma in pools of mucoid material, consistent with PMP.
  • The patient remains in good general condition with no signs of progression of PMP for 2 years, but with a gradual and progressive enlargement of the pancreatic cystic lesion.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / pathology. Chemotherapy, Cancer, Regional Perfusion. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Humans. Hyperthermia, Induced. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15983445.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 19
  •  go-up   go-down


17. Gadre SA, Perkins GH, Sahin AA, Sneige N, Deavers MT, Middleton LP: Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology; 2008 Nov;53(5):545-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion.
  • AIMS: Ductal carcinoma in situ (DCIS) associated with invasive mucinous carcinoma (IMC) has not been well characterized.
  • The aim was to characterize mucinous DCIS (mDCIS) of the breast and to describe, to our knowledge for the first time, neovascularization in mucin.
  • Anderson Cancer Center, whose diagnosis fulfilled the criteria of IMC or DCIS with mucin production.
  • Mucin was seen in the lumen of the ducts involved by DCIS in 88% of cases, mucin and vessels in 63.4% of cases and neither mucin nor vessels in 12.2%.
  • CONCLUSIONS: A significant number of mDCIS showed neovascularization in intraluminal mucin.
  • When identified on core needle biopsy, the presence of vascularized mucin should not be used alone to discriminate between invasive and in situ carcinoma.
  • A hypothesis proposed for the source of recruitment of vessels in the mucin is that mucin can promote neovascularization and that tumour cells invade not into the adjacent fibroconnective tissue, but rather into the mucinous, richly vascularized stroma that they have induced.
  • To our knowledge, this is the first study to characterize neovascularization within the mucinous component of DCIS associated with and without IMC.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / blood supply. Carcinoma, Intraductal, Noninfiltrating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Homeodomain Proteins / metabolism. Humans. Middle Aged. Mucins / metabolism. Neovascularization, Pathologic. Trans-Activators / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983463.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Mucins; 0 / Trans-Activators; 0 / Vascular Endothelial Growth Factor A; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


18. Avninder S, Bhatnagar A, Agrawal U, Saxena S: Isolated splenic metastasis from colorectal mucinous carcinoma. Int J Gastrointest Cancer; 2006;37(2-3):98-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic metastasis from colorectal mucinous carcinoma.
  • Isolated splenic metastases from colorectal carcinoma are rare and only 19 cases have been reported in English literature.
  • We report a case of isolated splenic metastasis in a 52-year-old man, occurring 9 years after the primary colorectal mucinous carcinoma was treated by anterior resection.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Colorectal Neoplasms / pathology. Splenic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 1997 Jun;90(6):633-6 [9191741.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1974 Jul;82(4):499-506 [4854372.001]
  • [Cites] Br J Clin Pract. 1989 Oct;43(10):385-6 [2629949.001]
  • [Cites] Am Surg. 2001 May;67(5):454-7 [11379648.001]
  • [Cites] South Med J. 1992 Oct;85(10 ):1003-5 [1411716.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Mar;23(1):143-6 [15149163.001]
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1345-8 [10528777.001]
  • [Cites] Mayo Clin Proc. 1969 Jan;44(1):40-5 [5767148.001]
  • [Cites] J Ultrasound Med. 1997 Nov;16(11):743-9 [9360238.001]
  • [Cites] Br J Surg. 1997 Jan;84(1):70 [9043458.001]
  • [Cites] Jpn J Clin Oncol. 2001 Jul;31(7):341-5 [11518749.001]
  • [Cites] J Pathol Bacteriol. 1965 Oct;90(2):515-21 [5849609.001]
  • [Cites] World J Surg Oncol. 2006 Jul 06;4:42 [16824207.001]
  • [Cites] Am J Clin Oncol. 2001 Jun;24(3):311-2 [11404507.001]
  • [Cites] J Korean Med Sci. 2000 Jun;15(3):355-8 [10895982.001]
  • [Cites] Eur J Cancer. 1995 Oct;31A(11):1885-6 [8541120.001]
  • [Cites] Clin Nucl Med. 1982 Jan;7(1):5-7 [7060295.001]
  • [Cites] Clin Nucl Med. 1986 Jul;11(7):491-2 [3731648.001]
  • [Cites] Eur J Surg Oncol. 1993 Oct;19(5):485-90 [8405487.001]
  • (PMID = 17827530.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Paner GP, Srigley JR, Radhakrishnan A, Cohen C, Skinnider BF, Tickoo SK, Young AN, Amin MB: Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol; 2006 Jan;30(1):13-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution.
  • Mucinous tubular and spindle cell carcinoma, a rare, recently described distinctive subtype of renal cell carcinoma, may have some morphologic similarities to the more common papillary renal cell carcinoma, particularly the basophilic (type 1) tumors with prominent solid growth pattern.
  • Tumor circumscription, compact tubular architecture, focal papillations, mucin production and foam cells (features seen in both papillary renal cell carcinoma and mucinous tubular and spindle cell carcinoma), as well as spindle cell morphology, have resulted in some cases sent to us in consultation with a question of possible sarcomatoid papillary renal cell carcinoma.
  • In this study, tissue microarrays with triplicate samples each from 27 mucinous tubular and spindle cell carcinomas and 20 papillary renal cell carcinomas were created to simulate experience in renal biopsy specimens.
  • From immunohistochemistry (IHC) data, published in the contemporary literature, a panel consisting of alpha-methylacyl-CoA racemase (AMACR), cytokeratin 7 (CK7), epithelial membrane antigen (EMA), renal cell carcinoma marker (RCC Ma), CD10, high molecular weight cytokeratin (HMWK), and c-kit was designed to test its utility in differential diagnosis.
  • The immunoreactivity in mucinous tubular and spindle cell carcinoma was AMACR 93%, CK7 81%, EMA 95%, RCC Ma 7%, CD10 15%, HMWK 15%, and c-kit 5% and in papillary renal cell carcinoma was AMACR 95%, CK7 65%, EMA 88%, RCC Ma 25%, CD10 80%, HWMK 15%, and c-kit 18%.
  • This largest study to date on IHC of mucinous tubular and spindle cell carcinoma dispels the specificity of AMACR for papillary renal cell carcinoma among the RCC subtypes.
  • The histogenesis of mucinous tubular and spindle cell carcinoma from the distal nephron continues to be debatable, as our study showed the expression of the proximal convoluted tubule-related marker AMACR among these tumors.
  • Thus, in tumors with predominant compact tubular growth and focal papillary architectures, careful attention to the presence of a low-grade spindle cell population may be helpful in the distinction of mucinous tubular and spindle cell carcinoma, as the key immunohistochemical stains for papillary renal cell carcinoma are also expressed in this subtype of renal cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Carcinoma, Papillary / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity


20. Min X, Guo JZ, Zhan Q: [Pathological analysis of pancreatic colloid carcinoma in 7 cases]. Zhonghua Zhong Liu Za Zhi; 2007 May;29(5):377-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathological analysis of pancreatic colloid carcinoma in 7 cases].
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / surgery. Diagnosis, Differential. Duodenal Neoplasms / metabolism. Duodenal Neoplasms / pathology. Duodenal Neoplasms / surgery. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Mucin-2. Mucins / metabolism. Neoplasm Invasiveness. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892136.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


21. Neeli S, Prabha V, Alur S, Malur P: Penile metastasis from primay mucinous adenocarcinoma of bladder. Indian J Urol; 2007 Jul;23(3):314-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile metastasis from primay mucinous adenocarcinoma of bladder.
  • Primary adenocarcinoma of the urinary bladder is not common.
  • Though penile metastases from transitional cell carcinoma are reported, such metastases from adenocarcinoma of urinary bladder is unknown.
  • We report a 55-year-old male having penile metastasis from primary mucinous adenocarcinoma of bladder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Urol. 1998 Aug;82(2):206-12 [9722755.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1990 Apr;143(4):671-8 [2179579.001]
  • [Cites] Br J Urol. 1971 Feb;43(1):4-15 [4926456.001]
  • [Cites] J Urol. 1964 May;91:538-48 [14154540.001]
  • [Cites] J Androl. 2003 Jul-Aug;24(4):499-500 [12826689.001]
  • [Cites] Urol Oncol. 2006 Jan-Feb;24(1):13-20 [16414487.001]
  • [Cites] Cancer. 1956 May-Jun;9(3):626-32 [13330017.001]
  • [Cites] Urology. 2003 Jul;62(1):145 [12837452.001]
  • (PMID = 19718338.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2721614
  • [Keywords] NOTNLM ; Adenocarcinoma / penile metastasis / urinary bladder neoplasm
  •  go-up   go-down


22. Nonaka D, Chiriboga L, Soslow RA: Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol; 2008 Oct;32(10):1566-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
  • The ovary is a common site of involvement for metastasis and the breast is one of the most common sources.
  • Metastatic breast carcinoma can mimic a primary ovarian carcinoma.
  • A total of 124 cases of ovarian carcinomas (84 serous papillary, 18 endometrioid, 12 mucinous, 10 clear cell) and 243 cases of invasive breast carcinomas (178 ductal, 65 lobular) were immunostained with Pax8 and WT1 by tissue microarrays to see the differential expression.
  • Pax8 reaction was found in 108 of 124 ovarian carcinomas (87.1%) generally in diffuse staining, including 81 of 84 serous papillary carcinomas (96.4%), 16 of 18 endometrioid carcinomas (88.9%), 10 of 10 clear cell carcinomas (100%), and 1 of 12 mucinous carcinomas (8.3%), whereas WT1 expression was seen in 78 of 124 ovarian carcinomas (62.9%), including 73 of 84 serous papillary carcinomas (86.9%), and 5 of 18 endometrioid carcinomas (27.8%), with no expression in all 10 clear cell carcinomas and 12 mucinous carcinomas.
  • All the mammary carcinomas were completely negative for Pax8, but WT1 expression was seen in 5 of 243 cases (2.1%).
  • Pax8 is a useful marker in the differential diagnosis of ovarian and breast carcinomas, and it seems to be superior to WT1 for the diagnosis of all types of nonmucinous ovarian carcinomas, notably clear cell and endometrioid types where WT1 expression is generally negative or only focal.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Invasiveness. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis. WT1 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724243.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / WT1 Proteins
  •  go-up   go-down


23. Ozan H, Ozerkan K, Aker S, Bülbül M: A case with three primary tumors of the ovary, endometrium and gallbladder. Eur J Gynaecol Oncol; 2008;29(5):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case with three primary tumors of the ovary, endometrium and gallbladder.
  • A 52-year-old patient underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy, bilateral pelvic and paraaortic lymph node dissection, and partial omentectomy for endometrial carcinoma accompanied by an adnexal mass.
  • Histopathology revealed a uterine endometrioid adenocarcinoma, a mucinous adenocarcinoma of the gallbladder, and an ovarian endometrioid carcinoma with a clear cell component.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Gallbladder Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051835.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Miyake Y, Hirokawa M, Norimatsu Y, Kanahara T, Monobe Y, Ohno S, Miyamoto T, Yakushiji H, Sakaguchi T, Aratake Y, Ohno E: Mucinous breast carcinoma with myoepithelial-like spindle cells. Diagn Cytopathol; 2009 Jun;37(6):393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous breast carcinoma with myoepithelial-like spindle cells.
  • But, we have frequently observed the spindle cells in smears from mucinous carcinoma of the breast.
  • Nineteen cases of breast mucinous carcinoma were used for cytological examination.
  • The mode of distribution of biochemical markers suggests that the positive cells for anti-CEA antibody and anti-EMA antibody are tumor cells compressed by mucin, while the vimentin-positive cells are fibroblasts.
  • We assert that the presence of spindle cells can be a characteristic feature of mucinous carcinoma of the breast.
  • Discrimination of the spindle cells in mucinous carcinoma from myoepithelial cells and naked bipolar nuclei in benign lesions was established here.
  • It should facilitate precise diagnosis of breast cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology


25. Shintaku M, Kushima R, Abiko K: Colloid carcinoma of the intestinal type in the uterine cervix: mucin immunohistochemistry. Pathol Int; 2010 Feb;60(2):119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colloid carcinoma of the intestinal type in the uterine cervix: mucin immunohistochemistry.
  • A case of colloid carcinoma (gelatinous carcinoma) of the intestinal type in the uterine cervix is reported along with the findings of an immunohistochemical study of intracytoplasmic mucus of the neoplastic cells.
  • The patient was a 69-year-old woman with a circumferential uterine cervical tumor measuring about 4 cm.
  • Histopathological examination of the hysterectomy specimen demonstrated typical features of colloid carcinoma.
  • The tumor consisted of numerous mucous nodules, and low-columnar or cuboidal cells with intracytoplasmic mucus lined the margins of the mucous nodules or floated within them.
  • Colloid carcinoma is a very rare variant of mucus-producing adenocarcinoma of the uterine cervix and probably a heterogeneous group that consists of neoplasms of different histogeneses, that is, neoplasms of endocervical, gastric, and intestinal origins.
  • Results of the immunohistochemical studies in the present case showed that neoplastic cells produced mucus of the large intestine type, thus verifying the presence of a distinct subtype of colloid carcinoma of the cervix that shows the intestinal phenotype.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Mucin-2 / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Humans. Hysterectomy. Immunohistochemistry. Mucin 5AC / biosynthesis. Mucin-6 / biosynthesis. Neoplasm Recurrence, Local / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398197.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-6
  •  go-up   go-down


26. Lane BR, Magi-Galluzzi C, Reuther AM, Levin HS, Zhou M, Klein EA: Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology; 2006 Oct;68(4):825-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the prostate does not confer poor prognosis.
  • OBJECTIVES: To report a series of patients with mucinous (colloid) adenocarcinoma (MC) at prostatectomy who were treated at a single institution from 1987 to 2005.
  • MC is a rare form of prostate cancer reported in some cases to have a more aggressive clinical course than conventional adenocarcinoma (AC).
  • METHODS: Radical prostatectomy specimens with mucinous features were identified from a database of 3613 consecutive patients.
  • Each case was reviewed again by a single pathologist who confirmed the diagnosis of MC in 14 patients.
  • MC was defined by the presence of pools of extracellular mucin in more than 25% of the tumor.
  • Eighteen additional cases were identified in which the mucinous component occupied only a small portion of the tumor and were referred to as AC with focal mucin (AFM).
  • RESULTS: No patients with MC or AFM died of disease, and 11 (91.7%) of 12 patients with MC and 9 (64.3%) of 14 patients with AFM were clinically and biochemically free of disease.
  • CONCLUSIONS: We report what we believe to be the largest published series of cases of MC (n = 14) with a median overall follow-up of 6.4 years.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070361.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Choi SC, Lee JK, Jung JH, Lee JS, Lee KH, Lee KT, Rhee JC, Jang KT, Choi SH, Heo JS, Choi DW, Lim JH: The clinicopathological features of biliary intraductal papillary neoplasms according to the location of tumors. J Gastroenterol Hepatol; 2010 Apr;25(4):725-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive colloid carcinoma mainly showed the intestinal cell type, and tubular carcinoma showed the pancreaticobiliary cell type.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Chi-Square Distribution. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Female. Gallstones / pathology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Republic of Korea. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492329.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Coffey JP, Hill JC: Breast sentinel node imaging with low-dose SPECT/CT. Nucl Med Commun; 2010 Feb;31(2):107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred and eighty-seven consecutive female patients (age range: 30-87 years) with biopsy proved breast carcinoma (18 lobular, 159 ductal carcinomas, two mucinous carcinomas and eight ductal carcinoma in situ) were injected with 40 MBq of 99mTc sulphur colloid, and underwent SPECT/CT scanning 45 min later.
  • Two patients had SLNs close to the site of periareolar injection; the remaining SLNs were located in the ipsilateral axillae.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Nucl Med Commun. 2010 May;31(5):476
  • (PMID = 19966597.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Guinebretière JM, Menet E, Tardivon A, Cherel P, Vanel D: Normal and pathological breast, the histological basis. Eur J Radiol; 2005 Apr;54(1):6-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormones are also thought to be the main determinant of the major benign and malignant pathologies encountered in the breast.
  • About 90% of malignant tumours are primary carcinoma.
  • The incidence of intra-ductal carcinoma has risen dramatically since the development of screening because of its ability to induce calcification.
  • Invasive carcinoma comprises numerous histological types.
  • Stromal reactions essentially determines their shape: a fibrous reaction commonly found in ductal carcinoma creates a stellate lesion while other stroma, inflammatory (medullary carcinoma), vascular (papillary carcinoma) or mucinous determine nodular lesions whose borders push the surrounding tissue.

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797289.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 22
  •  go-up   go-down


30. Yakirevich E, Sabo E, Klorin G, Alos L, Cardesa A, Ellis GL, Shumway BS, Gnepp DR: Primary mucin-producing tumours of the salivary glands: a clinicopathological and morphometric study. Histopathology; 2010 Sep;57(3):395-409
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucin-producing tumours of the salivary glands: a clinicopathological and morphometric study.
  • AIMS: To determine clinicopathological and morphometric features that discriminate between mucin-producing primary salivary gland carcinomas.
  • MATERIALS AND RESULTS: Fifteen mucin-producing tumours were stratified into five colloid carcinomas (CCs), four mucinous cystadenocarcinomas (MCAs), three mucin-rich salivary duct carcinomas (SDCs) and three mucin-rich mucoepidermoid carcinomas (MECs).
  • No disease-related mortality was observed in the CC group; one patient died in the MCA group, and one in the SDC group.
  • CONCLUSIONS: Strict morphological criteria of CC coupled with assessment of the tumour cell/stroma relationship and the nuclear features facilitate discrimination between mucinous tumours of salivary gland.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / pathology. Mucins / metabolism. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20738418.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


31. Choi YL, Kang SY, Shin YK, Choi JS, Kim SH, Lee SJ, Bae DS, Ahn G: Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch; 2006 Mar;448(3):331-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
  • RASSF1A promoter methylation rates in the various types of fresh ovarian tissues were as follows: serous cystadenoma (1/5), serous tumor of borderline malignancy (2/7), serous adenocarcinoma (4/10), mucinous cystadenoma (0/5), mucinous tumor of borderline malignancy (2/7), mucinous adenocarcinoma (3/6), transitional-cell carcinoma (1/3), clear-cell carcinoma (3/3), and malignant müllerian mixed tumor (3/3).
  • In archived serous tumor tissues, RASSF1A promoter hypermethylation was detected in serous cystadenoma (1/6, 16.6%), serous tumor of borderline malignancy (20/41, 48.8%), and in serous adenocarcinoma (25/50, 50%).
  • The RASSF1A promoter hypermethylation was frequently found in borderline tumors and carcinomas, suggesting that RASSF1A promoter hypermethylation may be a useful molecular marker for the early detection of ovarian tumors.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. DNA Methylation. Ovarian Neoplasms / genetics. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 1996 Oct;15(4):281-302 [8886876.001]
  • [Cites] Virchows Arch. 1998 Oct;433(4):305-9 [9808431.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6688-92 [11559536.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):147-50 [12527916.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3105-9 [11306494.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):994-1002 [14871978.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):212-7 [11668500.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):152-60 [1606537.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2212-22 [3179935.001]
  • [Cites] JAMA. 1995 Feb 8;273(6):491-7 [7837369.001]
  • [Cites] Oncogene. 2001 Mar 22;20(12):1509-18 [11313894.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):129-37 [14743218.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):805-12 [7547224.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):419-32 [11257616.001]
  • [Cites] Biol Rev Camb Philos Soc. 1996 Nov;71(4):529-43 [8923798.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3324-31 [12429618.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1664-8 [14996725.001]
  • [Cites] J Pathol. 2004 Jun;203(2):617-9 [15141374.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4662-7 [10493522.001]
  • [Cites] Oncogene. 1994 Dec;9(12):3467-74 [7970706.001]
  • (PMID = 16315018.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


32. Iwasaki N, Okabe Y, Tochio H, Ohshita Y, Nakamura H, Soga T, Fujimoto T, Wada M, Orino A: Evaluation of intratumoral hemodynamics with color Doppler imaging in patients with colorectal carcinoma: comparison between waveform analysis and histopathologic characteristics. J Med Ultrason (2001); 2005 Mar;32(1):13-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intratumoral hemodynamics with color Doppler imaging in patients with colorectal carcinoma: comparison between waveform analysis and histopathologic characteristics.
  • PURPOSE: We studied the relation between intratumoral hemodynamics and histopathologic characteristics in patients with colorectal carcinoma.
  • METHODS: A series of 82 patients with 28 well-differentiated adenocarcinomas, 40 moderately differentiated adenocarcinomas, 10 poorly differentiated adenocarcinomas, and 4 mucinous adenocarcinomas underwent color Doppler examination and surgical treatment.
  • Both were markedly higher in mucinous adenocarcinomas than in the other histopathologic types.
  • Furthermore, Vmax in well, moderately, and poorly differentiated adenocarcinomas did not differ significantly, although RI was negatively associated with the degree of differentiation.
  • CONCLUSIONS: We concluded that blood-flow analysis is closely associated with histopathologic findings of colorectal carcinomas and that it provides information useful in the clinical management of these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27276981.001).
  • [ISSN] 1346-4523
  • [Journal-full-title] Journal of medical ultrasonics (2001)
  • [ISO-abbreviation] J Med Ultrason (2001)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; color Doppler imaging / colorectal carcimoma / maximum velocity
  •  go-up   go-down


33. Goh PG, Moon HS, Sung JK, Jeong HY, Song KS: [A case of Peutz-Jeghers syndrome with intraductal papillary mucinous carcinoma of pancreas]. Korean J Gastroenterol; 2010 Jan;55(1):73-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Peutz-Jeghers syndrome with intraductal papillary mucinous carcinoma of pancreas].
  • Peutz-Jeghers syndrome (PJS), which is characterized by multiple hamartomatous polyps of the gastrointestinal tract and mucocutaneous pigmentation, is a rare autosomal dominant disease.
  • In particular, many studies have reported that patients with this syndrome have a high risk of gastrointestinal or extragastrointestinal malignancy including gastric, duodenal, jejunal, ileal, and colonic carcinoma as well as malignancies involving other organs such as the gallbladder, biliary tract, pancreas, tonsils, breast, and reproductive system.
  • In addition to that, there is no reported case of this syndrome with malignant tumor or intraductal papillary mucinous tumor of pancreas in Korea.
  • We experienced a case of PJS accompanying intraductal papillary mucinous carcinoma of the pancreas, therefore we report this case with literatures reviewed.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis. Peutz-Jeghers Syndrome / diagnosis

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098071.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


34. Määttä M, Bützow R, Luostarinen J, Petäjäniemi N, Pihlajaniemi T, Salo S, Miyazaki K, Autio-Harmainen H, Virtanen I: Differential expression of laminin isoforms in ovarian epithelial carcinomas suggesting different origin and providing tools for differential diagnosis. J Histochem Cytochem; 2005 Oct;53(10):1293-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of laminin isoforms in ovarian epithelial carcinomas suggesting different origin and providing tools for differential diagnosis.
  • Immunohistochemistry was used to study the distribution of laminin (Ln) chains, collagen types IV (alpha 1/2), VII, and XVIII and Lutheran antigen (Lu) in 36 frozen ovarian carcinoma samples.
  • Contrary to serous tumors, BMs of mucinous carcinomas showed Ln alpha4 chain, but not Ln alpha1 and beta2 chains.
  • Ln alpha1 chain was found in most endometrioid carcinomas, whereas chains of Ln-5 were only moderately detectable in comparison with serous and mucinous carcinomas.
  • The results suggest that the three types of ovarian carcinoma have distinct differences in their Ln distribution and can be grouped based on their expression pattern.
  • [MeSH-major] Adenocarcinoma / metabolism. Laminin / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Basement Membrane / metabolism. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / ultrastructure. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / ultrastructure. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / ultrastructure. Diagnosis, Differential. Epithelium / metabolism. Epithelium / ultrastructure. Female. Humans. Immunohistochemistry. Ovary / metabolism. Ovary / ultrastructure. Protein Isoforms / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923364.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Laminin; 0 / Protein Isoforms
  •  go-up   go-down


35. Taverna G, Corinti M, Colombo P, Grizzi F, Severo M, Piccinelli A, Giusti G, Benetti A, Zucali PA, Graziotti P: Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation. BMC Cancer; 2010;10:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation.
  • BACKGROUND: Appendiceal adenocarcinoma is rare with a frequency of 0.08% of all surgically removed appendices.
  • Few cases of appendiceal carcinoma infiltrating the bladder wall for spatial contiguity have been documented.
  • CASE PRESENTATION: A case is reported of a 45-years old woman with mucinous cystadenocarcinoma of the appendix with bladder metastasis.
  • Histopathology of the transurethral bladder resection revealed a bladder adenocarcinoma [6 cm (at the maximum diameter) x 2,5 cm; approximate weight: 10 gr] with focal mucinous aspects penetrating the muscle and perivisceral fat.
  • The subsequent pathological examination revealed a mucinous cystadenocarcinoma of the appendix with metastatic cells colonising the anterior bladder wall and several colic lymph nodes.
  • CONCLUSIONS: The rarity of the appendiceal carcinoma invading the urinary bladder and its usual involvement of nearest organs and the posterior bladder wall, led us to describe this case which demonstrates the ability of the appendiceal cancer to metastasize different regions of urinary bladder.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Cystadenocarcinoma, Mucinous / secondary. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2001 Apr;8(4):196-8 [11260355.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • [Cites] J Urol. 1980 Apr;123(4):590-1 [6245280.001]
  • [Cites] Can J Surg. 1982 Sep;25(5):553-5 [7116255.001]
  • [Cites] J Urol. 1987 Sep;138(3):617-8 [3041057.001]
  • [Cites] J Dig Dis. 2008 Aug;9(3):175-7 [18956597.001]
  • [Cites] Br J Urol. 1996 Aug;78(2):305-6 [8813936.001]
  • [Cites] Urol Int. 1997;58(2):124-7 [9096277.001]
  • [Cites] World J Gastroenterol. 2005 Aug 14;11(30):4761-3 [16094726.001]
  • [Cites] Int Urol Nephrol. 2006;38(3-4):481-2 [17160444.001]
  • [Cites] J Urol. 1995 Apr;153(4):1220-1 [7869505.001]
  • (PMID = 20178637.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2836301
  •  go-up   go-down


36. Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA: VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol; 2008 Mar;15(3):738-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.
  • BACKGROUND: High levels of vascular endothelial growth factor (VEGF) in ovarian cancer metastases are associated with a worse prognosis in patients treated with chemotherapy.
  • Patients with mucinous adenocarcinomas metastatic to the peritoneal surfaces can be treated with cytoreductive surgery, and both tumor grade and cytoreduction status are prognostic.
  • We hypothesized that angiogenic indices may be prognostic in patients undergoing cytoreductive surgery for mucinous adenocarcinoma of the appendix and colon.
  • CD 34 counts (blood vessels) and VEGF expression was evaluated by means of immunohistochemistry on specimens from patients undergoing cytoreductive surgery and intraperitoneal hyperthermic perfusion (IPHP) for mucinous adenocarcinoma.
  • RESULTS: A total of 26 males and 9 females, with a mean age of 50 years, underwent cytoreductive surgery and IPHP for mucinous adenocarcinoma of appendiceal (n = 32) or colonic (n = 3) origin.
  • With a mean follow-up of 18 months (range 1-63 months), 23 had disease recurrence and 12 were alive without recurrence.
  • CONCLUSIONS: These results suggest that markers of tumor angiogenesis may predict survival in patients with peritoneal surface metastases from mucinous adenocarcinoma.
  • These findings provoke the hypothesis that antiangiogenic therapies may be effective in patients with this devastating disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / therapy. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / therapy. Biomarkers, Tumor / biosynthesis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / therapy. Vascular Endothelial Growth Factor A / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043973.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


37. Leal RF, Ayrizono ML, Coy CS, Fagundes JJ, Góes JR: Mucinous adenocarcinoma derived from chronic perianal fistulas: report of a case and review of the literature. Tech Coloproctol; 2007 Jun;11(2):155-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma derived from chronic perianal fistulas: report of a case and review of the literature.
  • However, their evolution into adenocarcinoma is rare.
  • Diagnosis was confirmed by magnetic resonance imaging (MRI).
  • Histopathological sections indicated extramucosal mucinous adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / nursing. Anus Neoplasms / pathology. Rectal Fistula / pathology
  • [MeSH-minor] Aged. Chronic Disease. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2001 Aug;33(2):175-6 [11468456.001]
  • [Cites] J Comput Assist Tomogr. 2003 Jan-Feb;27(1):48-55 [12544243.001]
  • [Cites] Chirurgia (Bucur). 2003 Sep-Oct;98(5):459-64 [14999975.001]
  • [Cites] Dis Colon Rectum. 1993 Apr;36(4):383-7 [8458266.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):268-72 [3359895.001]
  • [Cites] Surg Today. 1996;26(9):707-10 [8883243.001]
  • [Cites] Eur Radiol. 2000;10(6):885-91 [10879695.001]
  • [Cites] Am J Clin Pathol. 1988 Jun;89(6):809-12 [2835897.001]
  • [Cites] Dig Surg. 2003;20(1):69-71 [12637812.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):233-7 [7840386.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s138-40 [15655599.001]
  • [Cites] Dis Colon Rectum. 1981 Oct;24(7):562-6 [6271516.001]
  • [Cites] Semin Surg Oncol. 1994 May-Jun;10(3):235-40 [8085101.001]
  • [Cites] Arch Surg. 1985 May;120(5):632-5 [3985803.001]
  • [Cites] J Surg Oncol. 1997 Mar;64(3):218-21 [9121153.001]
  • [Cites] Am Surg. 2003 Feb;69(2):166-9 [12641361.001]
  • (PMID = 17510737.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


38. Yang BL, Gu YF, Shao WJ, Chen HJ, Sun GD, Jin HY, Zhu X: Retrorectal tumors in adults: magnetic resonance imaging findings. World J Gastroenterol; 2010 Dec 14;16(46):5822-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presence of intracystic intermediate signal intensity was observed in one case of tailgut cyst with a component of adenocarcinoma.
  • Six solid tumors were malignant lesions and showed heterogeneous intensity on MRI.
  • Mucinous adenocarcinomas showed high signal intensity on T2-weighted and mesh-like enhancing areas on fat-suppressed T2-weighted images.
  • There was a fistula between the mass and anus with an internal opening in mucinous adenocarcinomas arising from anal fistula.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):855-8 [4053899.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):495-9 [8233293.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):731-2 [9294562.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jun;170(6):1488-90 [9609159.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):1056-8 [9715165.001]
  • [Cites] Clin Imaging. 2005 Jul-Aug;29(4):251-4 [15967315.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1581-7 [15937630.001]
  • [Cites] Yonsei Med J. 2005 Aug 31;46(4):555-61 [16127782.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):517-21 [16861558.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):381-5 [16909248.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):498-500 [17680300.001]
  • [Cites] Eur Radiol. 2008 Nov;18(11):2586-93 [18566821.001]
  • [Cites] Can J Surg. 2008 Dec;51(6):E115-6 [19057717.001]
  • [Cites] Am Surg. 2009 Mar;75(3):240-8 [19350861.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1344-7 [10811351.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):575-84 [11353107.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):705-14 [12023574.001]
  • [Cites] Tech Coloproctol. 2002 Apr;6(1):43-9 [12077641.001]
  • [Cites] Hum Pathol. 2002 May;33(5):456-8 [12094369.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):21-6 [12689667.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):55-7 [12750956.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):880-6 [12788424.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):2053-4 [12942309.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • (PMID = 21155003.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3001973
  •  go-up   go-down


39. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S: Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res; 2007 Jan 15;13(2 Pt 1):408-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Mutational analysis of PIK3CA was done in 188 primary breast cancers of Japanese women.
  • RESULTS: Missense mutations of PIK3CA were found in 44 of 158 invasive ductal carcinomas, 4 of 10 invasive lobular carcinomas, 1 of 4 mucinous carcinomas, 2 of 2 squamous carcinomas, and 2 of 2 apocrine carcinomas, but no mutation was found in 12 noninvasive ductal carcinomas.
  • PIK3CA mutations were significantly (P < 0.05) associated with a favorable prognosis, and multivariate analysis showed that PIK3CA mutation status was a significant (P < 0.05) prognostic factor independent of the other conventional prognostic factors.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma / genetics. Carcinoma / pathology. DNA Mutational Analysis. Mutation. Phosphatidylinositol 3-Kinases / genetics
  • [MeSH-minor] Catalytic Domain. Disease-Free Survival. Female. Humans. Japan. Lymphatic Metastasis. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202311.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  •  go-up   go-down


40. Zen Y, Fujii T, Itatsu K, Nakamura K, Konishi F, Masuda S, Mitsui T, Asada Y, Miura S, Miyayama S, Uehara T, Katsuyama T, Ohta T, Minato H, Nakanuma Y: Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. Mod Pathol; 2006 Sep;19(9):1243-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary cystic tumors, which are also called biliary cystadenoma and cystadenocarcinoma, are thought to be a heterogeneous disease entity, and some of them are known to show a luminal communication to the bile duct.
  • They were multilocular (eight cases) or unilocular (one case), and all cases contained mucinous fluid.
  • Biliary cystic tumors examined in this study were histologically adenoma (one case), adenocarcinoma in situ (six cases), and adenocarcinoma associated with microinvasive mucinous carcinoma (two cases).
  • One case of adenocarcinoma in situ also had the adenoma component (adenocarcinoma in adenoma).
  • Dysplastic mucinous epithelium proliferated in flat, micropapillary and papillary fashions within the intracystic spaces.
  • These clinicopathological features resembled those of intraductal papillary neoplasm of the bile duct, which had been reported as a biliary counterpart of pancreatic intraductal papillary mucinous neoplasm.
  • In conclusion, biliary cystic tumors with bile duct communication could be regarded as intraductal papillary neoplasm with a prominent cystic dilatation of the bile duct and mucin retention, rather than true biliary cystic neoplasms.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Cystadenocarcinoma / pathology. Cystadenoma / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma in Situ. Disease-Free Survival. Female. Fluorescent Antibody Technique, Indirect. Homeodomain Proteins / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucin-1 / metabolism. Mucin-2. Mucins / secretion. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 2 June 2006.
  • (PMID = 16741522.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


41. Yvgenia R, Ben Meir D, Sibi J, Koren R: Mucinous adenocarcinoma of posterior urethra. Report of a case. Pathol Res Pract; 2005;201(2):137-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of posterior urethra. Report of a case.
  • Primary carcinoma of the male urethra accounts for less than 1% of malignancies in males.
  • Mucinous adenocarcinoma of the urethra is extremely rare, and its biologic behavior is not well known.
  • We report a case of mucinous adenocarcinoma showing the histologic features of colloid adenocarcinoma that appears to have evolved either by neoplastic degeneration of goblet cells found in the urethral epithelium or by malignant degeneration of persistent glandular elements of uretheritis cystica and glandularis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901135.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Tsai WP, Shieh SJ, Lin BW: Extensive perineal and pelvic defects reconstructed simultaneously using bilateral pedicled gracilis and rectus abdominis muscle flaps after en-bloc excision of locally invasive perineal mucinous adenocarcinoma 1. Scand J Plast Reconstr Surg Hand Surg; 2009;43(5):286-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive perineal and pelvic defects reconstructed simultaneously using bilateral pedicled gracilis and rectus abdominis muscle flaps after en-bloc excision of locally invasive perineal mucinous adenocarcinoma 1.
  • We report a case of successful simultaneous reconstruction of pelvic and perineal defects using bilateral pedicled gracilis and inferiorly based rectus abdominis muscle flaps after en-bloc excision of the tumour and abdominoperineal resection of locally advanced invasive perineal mucinous adenocarcinoma originating from a chronic anal fistula.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863433.001).
  • [ISSN] 1651-2073
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Sultan I, Rodriguez-Galindo C, El-Taani H, Pastore G, Casanova M, Gallino G, Ferrari A: Distinct features of colorectal cancer in children and adolescents: a population-based study of 159 cases. Cancer; 2010 Feb 1;116(3):758-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: From January 1973 through December 2005, only 159 children/adolescents (ages 4-20 years) were reported with a diagnosis of colorectal cancer.
  • Adenocarcinoma was the most common histotype in both adults and pediatric patients; however, children/adolescents had more unfavorable histotypes (ie, mucinous adenocarcinoma [22%] and signet ring cell carcinoma [18%]) when compared with adults (10% and 1%, respectively; P < .001).
  • [MeSH-major] Colorectal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Age Distribution. Child. Female. Humans. Male. Neoplasms, Multiple Primary / epidemiology. Population Surveillance. Prognosis. SEER Program. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Cancer Society.
  • (PMID = 19957323.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. McCluggage WG, Young RH: Primary ovarian mucinous tumors with signet ring cells: report of 3 cases with discussion of so-called primary Krukenberg tumor. Am J Surg Pathol; 2008 Sep;32(9):1373-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian mucinous tumors with signet ring cells: report of 3 cases with discussion of so-called primary Krukenberg tumor.
  • The distinction between a primary ovarian mucinous carcinoma or even a borderline mucinous tumor and a metastatic mucinous carcinoma may be difficult.
  • A constellation of clinical, gross pathologic and morphologic features is used in this distinction.
  • One of the most important morphologic features suggesting a metastatic mucinous carcinoma in the ovary is the presence of signet ring cells; these are considered rare in primary ovarian mucinous tumors.
  • In this study, we report 3 primary ovarian mucinous tumors with a component of signet ring cells.
  • In one case, the neoplasm had the architecture of a mucinous adenofibroma but had frankly malignant cells lining glands and forming solid aggregates of cells.
  • The third was mostly a mucinous cystadenoma.
  • Features favoring a primary rather than a metastatic neoplasm are unilateral tumor, low stage, background of adenofibroma or cystadenoma, associated endometriosis in 1 case and an absence of features which are characteristic of secondary mucinous carcinomas in the ovary, such as surface tumor deposits, a nodular growth pattern, and lymphovascular permeation.
  • Immunohistochemistry is of limited value because of overlapping immunophenotype between a primary ovarian mucinous tumor and a metastasis from the stomach, pancreas, biliary tree, appendix, or colorectum, the most likely primary sites for a secondary exhibiting similar features.
  • Our study illustrates that signet ring cells occur rarely in a primary ovarian mucinous tumor; even when conspicuous the features differ from those of the usual Krukenberg tumor.
  • At least some cases of so-called primary Krukenberg tumor may be similar to our cases.
  • However, the designation primary Krukenberg tumor should not be used as, apart from the signet ring cells, a resemblance to a "true" Krukenberg tumor of the secondary type is limited.
  • The tumors should be classified according to the underlying background neoplasm with a notation concerning the signet ring cell component.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Krukenberg Tumor / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670351.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Irving JA, Vasques DR, McGuinness TB, Young RH: Krukenberg tumor of renal pelvic origin: report of a case with selected comments on ovarian tumors metastatic from the urinary tract. Int J Gynecol Pathol; 2006 Apr;25(2):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In approximate descending order of frequency, this subset of secondary ovarian neoplasms includes renal cell carcinoma, transitional cell carcinoma of the urinary bladder, and urachal adenocarcinomas.
  • These tumors usually raise a differential in turn of primary ovarian clear cell, transitional cell, or mucinous carcinomas.
  • Only rare metastatic signet-ring adenocarcinomas of the bladder have shown the features of a Krukenberg tumor.
  • We report the case of a 74-year old woman with bilateral Krukenberg tumors metastatic from a primary renal pelvic transitional cell carcinoma with glandular and signet-ring cell differentiation.
  • This unique case reinforces that tumors with signet-ring cell morphology have a propensity to metastasize to the ovary, and indicates that renal pelvic carcinoma rarely may be the source of Krukenberg tumors.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Carcinoma, Transitional Cell / secondary. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary. Urologic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633063.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


46. Gupta R, Mortelé KJ, Tatli S, Girshman J, Glickman JN, Levy AD, Erturk SM, Heffess CS, Banks PA, Silverman SG: Pancreatic intraductal papillary mucinous neoplasms: role of CT in predicting pathologic subtypes. AJR Am J Roentgenol; 2008 Nov;191(5):1458-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraductal papillary mucinous neoplasms: role of CT in predicting pathologic subtypes.
  • OBJECTIVE: The objective of our study was to evaluate whether CT can be used to predict the pathologic subtypes of pancreatic intraductal papillary mucinous neoplasms (IPMNs).
  • MATERIALS AND METHODS: Three radiologists, blinded to the pathologic IPMN subtype, retrospectively and independently reviewed the preoperative CT scans of 38 patients with surgically resected pancreatic IPMN: 11 intraductal papillary mucinous adenomas, 11 intraductal papillary mucinous carcinomas, and 16 intraductal papillary mucinous carcinomas with invasion.
  • Interobserver agreement of the CT diagnosis of pathologic subtype and agreement between the CT diagnosis and pathologic subtype were also studied (kappa statistic).
  • RESULTS: Predominant main pancreatic duct (MPD) involvement (p = 0.04) and a wide (> 1 cm) connection of a side-branch lesion with the MPD (p = 0.03) correlated with intraductal papillary mucinous carcinoma with invasion.
  • Both interobserver agreement of CT diagnosis (range, 0.004-0.359) and agreement between CT diagnosis and pathologic subtype (range, 0.046-0.317) ranged from slight to fair.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Carcinoma, Pancreatic Ductal / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] AJR Am J Roentgenol. 2008 Dec;191(6):1876
  • (PMID = 18941085.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D: Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol; 2008 Sep;110(3):408-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
  • OBJECTIVES: Pelvic serous carcinomas are classified according to the location of greatest mass of tumor as ovarian, peritoneal or fallopian tube.
  • RESULTS: Of sixteen cases, twelve were high-grade serous carcinoma, stage III, and four cases were stage I, two borderline mucinous, one borderline serous, and one low-grade mucinous carcinoma.
  • Ten cases of high-grade serous carcinoma showed either unilateral fallopian tube mucosal involvement (n = 7) or tubal obliteration ipsilateral to the dominant ovarian mass (n = 3), compared to none of the other carcinomas.
  • FISH analysis showed similar copy number changes in the ovarian and fallopian tube mucosal carcinoma in 3 cases, suggesting a unifocal origin; one case had differences suggesting multifocal origin of cancer.
  • From risk-reducing salpingectomy cases, the multiple foci of tubal intraepithelial carcinoma and focus of invasive carcinoma showed similar gene copy number changes within each case, suggesting monclonality.
  • In situ epithelial lesions of the fallopian tube from risk-reducing salpingectomies show gene copy abnormalities consistent with these being early lesions of serous carcinoma and suggest that chromosomal instability is a very early event in serous carcinogenesis.
  • [MeSH-major] Chromosomal Instability. Cystadenocarcinoma, Serous / genetics. Fallopian Tube Neoplasms / genetics. Neoplasms, Multiple Primary / genetics. Ovarian Neoplasms / genetics. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18597838.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


48. Danova NA, Robles-Emanuelli JC, Bjorling DE: Surgical excision of primary canine rectal tumors by an anal approach in twenty-three dogs. Vet Surg; 2006 Jun;35(4):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of primary canine rectal tumors by an anal approach in twenty-three dogs.
  • OBJECTIVE: To describe an anal approach for excision of primary rectal tumors in dogs and to report outcome.
  • ANIMALS: Dogs (n=23) with primary rectal tumors.
  • METHODS: Review of medical records (1990-2000) of dogs with primary rectal neoplasia excised surgically using an anal approach with rectal prolapse.
  • RESULTS: Each dog had only 1 tumor type (adenocarcinoma [8], solitary polyp [5], carcinoma [4], plasmacytoma [2], adenoma [1], leiomyoma [1], mucinous carcinoma [1], and papilloma [1]).
  • The primary tumor was incompletely excised in 1 dog (4.3%), and local recurrence occurred 16 and 24 months after surgery in 2 dogs.
  • Mean postoperative disease-free interval for these 18 dogs was 36.8 months (range 5-84 months).
  • [MeSH-minor] Adenocarcinoma / surgery. Adenocarcinoma / veterinary. Animals. Disease-Free Survival. Dogs. Female. Male. Polyps / surgery. Polyps / veterinary. Postoperative Complications / veterinary. Records as Topic / veterinary. Retrospective Studies. Treatment Outcome. Wisconsin / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756613.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Kountourakis P, Ardavanis A, Mantzaris I, Mitsaka D, Rigatos G: Urachal mucinous adenocarcinoma: a case report. J BUON; 2007 Oct-Dec;12(4):547-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal mucinous adenocarcinoma: a case report.
  • Adenocarcinomas account for 0.5-2% of all bladder cancers.
  • Urachal carcinoma is a rare neoplasm which represents 0.01% of all cancers in adults and account for one third of bladder adenocarcinomas.
  • A 65-year-old white man with an urachal mucinous adenocarcinoma is reported.
  • He underwent a partial cystectomy and en block excision of the umbilical ligament and remains disease-free after one year.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Urachus. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067216.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


50. Sengul N, Wexner SD, Woodhouse S, Arrigain S, Xu M, Larach JA, Ahn BK, Weiss EG, Nogueras JJ, Berho M: Effects of radiotherapy on different histopathological types of rectal carcinoma. Colorectal Dis; 2006 May;8(4):283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of radiotherapy on different histopathological types of rectal carcinoma.
  • BACKGROUND: Down staging by pre-operative chemoradiotherapy is currently considered part of the standard therapeutic approach to rectal carcinoma.
  • The aim of this study was to assess the response to chemoradiotherapy of different histopathological types of rectal carcinoma with emphasis on the mucinous variant.
  • METHOD: Between 1997 and 2002, 71 patients who received pre-operative chemoradiotherapy followed by surgery for rectal carcinoma were enrolled in the study.
  • Staging of the rectal carcinoma was performed according to transrectal ultrasound findings (TN score) prior to the chemoradiotherapy.
  • Tumours were classified as mucinous or nonmucinous according to pre- and post-operative biopsy and specimen histopathological types.
  • Higher TRG was associated with a smaller decrease in TN staging.
  • TRG was significantly lower in the nonmucinous compared to the mucinous group and the decrease in TN grade was significantly larger in the nonmucinous group.
  • CONCLUSION: Mucinous carcinoma was associated with a lower response to pre-operative chemo-radiotherapy in this group of rectal carcinoma patients.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630231.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


51. Taneous M, Ramalingam P, Mode DG, Heiner JG, Terris MK, Lee JR: Primary mucinous adenocarcinoma in a defunctionalized urinary bladder: a case report. J Med Case Rep; 2009;3:9306
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma in a defunctionalized urinary bladder: a case report.
  • Transitional cell and squamous cell carcinomas are the most common but there are three reported cases of mucinous adenocarcinoma.
  • CASE PRESENTATION: We report a 57-year-old Caucasian man presenting with penile discharge for 30 years following ileal conduit surgery for neurogenic bladder, and who was found to have primary mucinous adenocarcinoma of his defunctionalized bladder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1997 Sep;50(3):427-31 [9301710.001]
  • [Cites] Eur Urol. 1996;29(3):308-11 [8740037.001]
  • [Cites] Urology. 1995 Jul;46(1):107-10 [7604470.001]
  • [Cites] Ann Pathol. 1995;15(2):131-3 [7755802.001]
  • [Cites] J Urol. 2002 Apr;167(4):1782-3 [11912412.001]
  • [Cites] Scand J Urol Nephrol. 1985;19(4):303-4 [4089557.001]
  • [Cites] Urology. 1984 Aug;24(2):192-5 [6087535.001]
  • [Cites] JAMA. 1982 Dec 3;248(21):2885-6 [7143654.001]
  • [Cites] J Urol. 2004 Sep;172(3):831-8 [15310979.001]
  • [Cites] Urology. 1991 Apr;37(4):315-21 [2014595.001]
  • (PMID = 20062735.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803829
  •  go-up   go-down


52. Nara M, Hashi A, Murata S, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K: Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol; 2007 Aug;106(2):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection.
  • OBJECTIVES: The aim of this study was to investigate differences in the process of carcinogenesis between adenocarcinoma coexistent with LEGH and conventional adenocarcinoma.
  • METHODS: Using the surgical pathology files of patients who visited the University of Yamanashi Hospital, Yamanashi Central Hospital and Kofu Municipal Hospital between 1996 and 2005, pathological diagnoses were reevaluated based on criteria for the diagnosis of LEGH by Nucci et al.
  • As for the cases including adenocarcinoma with LEGH: (a) we created a map showing position of the LEGH component and adenocarcinoma component and squamo-columnar junction (SCJ) in HE-stained specimens, (b) immunohistochemical staining was performed using antibodies to CEA, HIK1083 and p53, and (c) detection of HPV DNA was performed using PCR and in situ hybridization (ISH).
  • RESULTS: Endocervical adenocarcinoma was observed coexistent with LEGH in 5 cases (19.2%). (a) LEGH was located in a remote place from the SCJ.
  • Sizes of lesions in the 5 cases ranged from 18 to 35 mm in width and 7 to 16 mm in depth. (b) HIK1083 was diffusely immunopositive in the cytoplasm of LEGH component and focal immunopositive in 4 cases with adenocarcinoma component.
  • Immunopositivity for CEA was seen in the cytoplasm of adenocarcinoma component in 4 cases.
  • Immunopositivity for p53 was seen in adenocarcinoma component nuclei in 2 cases. (c) HPV DNA was not detected using PCR and ISH in either LEGH or adenocarcinoma components.
  • CONCLUSIONS: The present study suggests that clear differences exist in the process of carcinogenesis between adenocarcinoma associated with LEGH and conventional adenocarcinoma.
  • LEGH may represent a precursor of cervical adenocarcinoma independent of HPV infection.
  • As LEGH displays characteristics of precancerous mucinous adenocarcinoma, surgical treatment should be considered for LEGH growing beyond a certain size.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Neoplasms, Glandular and Epithelial / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


53. Georgescu CV, Săftoiu A, Georgescu CC, Ciurea R, Ciurea T: Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma. J Gastrointestin Liver Dis; 2007 Jun;16(2):133-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma.
  • AIM: To investigate the expression of PCNA, Ki-67 and p53 antibodies in colorectal carcinomas and to establish the relationship between these markers and some particular histological findings of colorectal carcinomas.
  • MATERIAL AND METHODS: We determined immunohistochemically the expression of PCNA, Ki-67 and p53 antibodies in 41 cases of colorectal carcinomas.
  • RESULTS: In adenocarcinomas, the tumor proliferative activity, detected with PCNA and Ki-67 antibodies, increased with the histological grade.
  • Mucinous adenocarcinomas had a mean PCNA LI of 50% and a mean Ki-67 LI of 32%, while signet ring carcinomas had a mean PCNA LI of 70% and a mean Ki-67 LI of 45%.
  • The proliferative activity in the foci of squamous metaplasia was lower than the proliferative activity of malignant areas in the analyzed adenocarcinomas.
  • In adenocarcinomas, the p53 positive rate increased with the dedifferentiation of these tumours.
  • Only 16.66% of the cases of carcinomas with mucus secreting cells overexpressed p53, while adenocarcinomas overexpressed this protein in many more cases (65.71% of the cases).
  • CONCLUSIONS: The foci of squamous metaplasia, present in colorectal adeno-carcinomas, do not seem to influence the increase of the tumours.
  • The p53 overexpression was associated with non mucinos colorectal carcinomas and with the histological grade of colorectal adenocarcinomas.
  • The p53 over expression tended to be more frequent in colorectal carcinomas with high proliferative activity.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Ki-67 Antigen / analysis. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592558.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


54. El-Ghobashy A, Ohadike C, Wilkinson N, Lane G, Campbell JD: Recurrent urachal mucinous adenocarcinoma presenting as bilateral ovarian tumors on cesarean delivery. Int J Gynecol Cancer; 2009 Dec;19(9):1539-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent urachal mucinous adenocarcinoma presenting as bilateral ovarian tumors on cesarean delivery.
  • Such metastases could mimic primary mucinous ovarian adenocarcinomas.
  • Primary adenocarcinoma of the bladder accounts for less than 1% of all bladder malignancies; one third of these tumors are urachal in origin.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Cesarean Section. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Urachus
  • [MeSH-minor] Adult. Delivery, Obstetric. Diagnosis, Differential. Female. Humans. Pregnancy


55. Li LJ, Wang ZQ, Wu BP: Peutz-Jeghers syndrome with small intestinal malignancy and cervical carcinoma. World J Gastroenterol; 2008 Dec 28;14(48):7397-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peutz-Jeghers syndrome with small intestinal malignancy and cervical carcinoma.
  • Because of small intestinal obstruction, she received the small intestinal polypectomy in 2001, and the pathological diagnosis was Peutz-Jeghers polyp canceration (mucinous adenocarcinoma, infiltrating full-thickness of the intestine).
  • We kept a follow-up study on her and found that she suffered from cervical cancer in 2007, with a pathological diagnosis of cervical adenosquamous carcinoma.The patient presented with typical features of PJS, but without a family history.
  • [MeSH-major] Adenocarcinoma / complications. Carcinoma, Adenosquamous / complications. Ileal Neoplasms / complications. Peutz-Jeghers Syndrome / complications. Uterine Cervical Neoplasms / complications


56. Sharma SG, Gokden M, McKenney JK, Phan DC, Cox RM, Kelly T, Gokden N: The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol; 2010 Dec;18(6):494-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features.
  • PAX-2, a homeogene expressed during kidney development, has been studied as a marker of renal origin in both primary and metastatic clear cell renal cell carcinoma (RCC), but not in papillary neoplasms or in comparison with RCC marker (RCCma).
  • Of the NRCPN, 9/66 (14%) is positive for PAX-2 [4/10 (40%) ovarian papillary serous carcinomas, 5/9 (56%) uterine papillary serous carcinomas]; RCCma was positive in 28/66 (42%), including 9/9 (100%) papillary thyroid carcinomas, 8/10 (80%) ovarian papillary serous carcinomas, 4/9 (44%) uterine papillary serous carcinomas, 1/10 (10%) papillary urothelial carcinomas, 1/2 (50%) intraductal papillary mucinous carcinomas of the pancreas, 3/3 (100%) choroid plexus papillomas, 1/1 (100%) pituitary adenoma with papillary features, and 1/2 (50%) lung adenocarcinomas with papillary features.
  • The sensitivity of PAX-2+/RCCma+ immunophenotype for PRCC was 58% with a specificity of 54%.
  • There is significant overlap between the expressions of these markers in PRCC and NRCPN; however, the positivity of RCCma and/or PAX-2 is 100% sensitive for PRCC and may prove useful in the initial work up of metastases of unknown primary.
  • PAX-2 and RCCma immunohistochemistry should be interpreted with caution in papillary neoplasms, with particular attention to the possibility of ovarian and uterine papillary serous carcinomas, which can express both PAX-2 and RCCma.
  • [MeSH-major] Advanced Glycosylation End Product-Specific Receptor / analysis. Biomarkers, Tumor / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Renal Cell / chemistry. Carcinoma, Renal Cell / diagnosis. Immunohistochemistry. Kidney Neoplasms / chemistry. Kidney Neoplasms / diagnosis. PAX2 Transcription Factor
  • [MeSH-minor] Biopsy. Cell Nucleus / chemistry. Diagnosis, Differential. Female. Humans. Kidney / pathology. Neoplasm Metastasis. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21102195.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor
  •  go-up   go-down


57. Kinkor Z, Michal M: [Syndrome of pseudomyxoma peritonei--description of three cases and survey of the problem]. Ceska Gynekol; 2005 Jan;70(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Syndrome of pseudomyxoma peritonei--description of three cases and survey of the problem].
  • OBJECTIVE: To describe personal experience with three heterogeneous cases of pseudomyxoma peritonei.
  • Clinical presentation of three cases of pseudomyxoma peritonei documented is in details including long follow up.
  • CONCLUSION: Pseudomyxoma peritonei is a clinical syndrome defined as presence of massive mucinous, viscous material in the peritoneal cavity, both floating and adhering to serosal surface (jelly-belly).
  • First and more frequent, so-called disseminated peritoneal adenomucinosis, where primary low grade (benign) mucinous appendiceal tumor is almost constant finding, often recurs but displays favorable prognosis.
  • Second, so-called peritoneal mucinous carcinomatosis is an extraordinary manifestation of peritoneal carcinosis following generalization of the gastrointestinal mucinous adenocarcinoma.
  • A normal macroscopic finding on appendix or "uneventful" appendectomy in anamnesis is not unusual.

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779299.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


58. Yamaguchi T, Kagawa R, Sakata S, Takahashi H, Takeda R, Nishizaki D: Successful sphincter-sparing local excision for mucinous adenocarcinoma associated with chronic fistula in ano using preoperative MRI evaluation. Int Surg; 2008 Jul-Aug;93(4):220-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful sphincter-sparing local excision for mucinous adenocarcinoma associated with chronic fistula in ano using preoperative MRI evaluation.
  • A 78-year-old man with a 10-year history of ischiorectal abscess was referred to our hospital because purulent drainage from an external opening changed to mucoid drainage.
  • By the brushing cytology of fistula ano, mucinous adenocarcinoma was found.
  • T2-weighted magnetic resonance imaging (MRI) indicated that a mucinous adenocarcinoma was localized within the abscess and the fistula, and was not invasive neoplasm.
  • The pathological findings indicated that mucinous adenocarcinoma arose from anal glands, developed lining the preexisting abscess and fistula wall.
  • Five years after the resection, he remains asymptomatic and free of disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Rectal Fistula / complications. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19731857.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


59. Arai T, Kasahara I, Sawabe M, Kanazawa N, Kuroiwa K, Honma N, Aida J, Takubo K: Microsatellite-unstable mucinous colorectal carcinoma occurring in the elderly: comparison with medullary type poorly differentiated adenocarcinoma. Pathol Int; 2007 Apr;57(4):205-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite-unstable mucinous colorectal carcinoma occurring in the elderly: comparison with medullary type poorly differentiated adenocarcinoma.
  • Mucinous carcinoma and poorly differentiated adenocarcinoma of the large intestine have a high frequency of microsatellite instability, and their occurrence increases gradually with age.
  • To elucidate the clinicopathological and immunohistochemical features of microsatellite-unstable mucinous carcinoma and compare the tumor with medullary type poorly differentiated adenocarcinoma, the clinicopathological status and expression of mucin core and hMLH1 proteins were studied in 15 microsatellite-unstable and 20 microsatellite-stable mucinous colorectal carcinomas occurring in elderly patients, and compared with 23 cases of medullary type poorly differentiated adenocarcinoma in which 21 cases were microsatellite-unstable.
  • Thirteen (87%) of 15 microsatellite-unstable carcinomas exhibited absent hMLH1 expression compared with three (15%) of 20 microsatellite-stable carcinomas (P < 0.01).
  • The proportion (87%) of positive MUC5AC expression in microsatellite-unstable mucinous carcinoma was significantly higher than that (45%) in microsatellite-stable mucinous carcinoma (P = 0.01).
  • Compared with microsatellite-stable mucinous carcinoma, microsatellite-unstable mucinous carcinomas were significantly associated with a proximal location, intra- and peritumoral inflammatory cell infiltration, frequent MUC5AC expression, a low incidence of lymph node metastasis and absent hMLH1 protein expression, which is not different to medullary type poorly differentiated adenocarcinoma except for MUC2 expression and age-related occurrence.
  • These results suggest that microsatellite-unstable mucinous carcinoma occurring in the elderly shares clinicopathological and molecular features with medullary type poorly differentiated adenocarcinoma and that microsatellite instability with absent hMLH1 expression plays an important role in the development of these two carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Aging / genetics. Carrier Proteins / metabolism. Colorectal Neoplasms / genetics. Microsatellite Instability. Nuclear Proteins / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Mucin 5AC. Mucins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316416.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 0 / Nuclear Proteins
  •  go-up   go-down


60. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol; 2009 Jun;113(3):331-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
  • OBJECTIVE: We conducted the present study to clarify the clinicopathological characteristics of mucinous adenocarcinoma.
  • METHODS: Two hundred twenty-five patients were diagnosed with mucinous adenocarcinoma at individual institutes and underwent primary treatment between 1998 and 2003.
  • Of 189 patients undergoing central pathological review, 64 patients (33.9%) were diagnosed with mucinous invasive adenocarcinoma, 45 mucinous intraepithelial carcinoma, and 42 mucinous tumor of borderline malignancy.
  • Twenty-five patients were diagnosed with other histological subtypes, including 8 endometrioid adenocarcinoma, 5 clear cell carcinoma, 3 serous adenocarcinoma, and 4 mixed type.
  • There were 13 cases of metastatic mucinous adenocarcinoma, including 7 pseudomyxoma peritonei.
  • Four hundred thirty-three patients with serous adenocarcinoma were used as controls.
  • RESULTS: Forty-five patients with mucinous invasive carcinoma were in FIGO I-II stages and 19 in III-IV stages.
  • There was no difference in the outcome between mucinous invasive adenocarcinoma and serous adenocarcinoma in I-II stage patients and III-IV stage patients with optimal operation.
  • In contrast, patients with mucinous invasive adenocarcinoma receiving suboptimal operation showed a significantly worse prognosis (survival rate: 27.8% vs. 61.5%).
  • The response rate to chemotherapy for mucinous invasive adenocarcinoma was significantly lower than for serous adenocarcinoma (12.5% vs. 67.7%).
  • CONCLUSIONS: The diagnosis of mucinous invasive adenocarcinoma was difficult.
  • Since patients with mucinous invasive adenocarcinoma had a lower response to chemotherapy, aggressive cytoreductive surgery was an effective treatment to improve the prognosis for advanced stage patients.
  • A new chemotherapeutic regimen should be established for mucinous adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275957.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Reid-Nicholson M, Iyengar P, Friedlander MA, Lin O: Fine needle aspiration biopsy of primary mucinous carcinoma of the skin: a case report. Acta Cytol; 2006 May-Jun;50(3):317-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy of primary mucinous carcinoma of the skin: a case report.
  • BACKGROUND: Primary mucinous carcinoma of the skin is a rare neoplasm of sweat gland origin.
  • To the best of our knowledge, this is the first reported case with a sentinel lymph node biopsy.
  • CASE: A 78-year-old woman presented with a 3-cm left scalp mass at an outside institution.
  • Following incomplete excision, multiple subcentimeter nodules developed in the skin adjacent to the biopsy site.
  • FNAB of the nodules confirmed a recurrence of mucinous carcinoma.
  • Clinical examination and extensive radiographic studies did not reveal primary disease elsewhere, thus supporting a diagnosis of primary mucinous carcinoma of the skin.
  • The patient declined adjuvant therapy and was disease free 6 months after the initial diagnosis.
  • CONCLUSION: Cutaneous mucinous carcinoma is a tumor characterized by bland histocytologic features and abundant extracellular pools of mucin.
  • Numerous benign and malignant mucin-producing primary and secondary mimics exist, and immunohistochemistry offers limited benefits in differentiating them.
  • Cytologic diagnosis of primary mucinous carcinoma of the skin is possible; however, correlation of clinical, radiologic and pathologic features is necessary to arrive at an accurate diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Head and Neck Neoplasms / pathology. Scalp. Skin / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780028.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


62. Jin HY, Liu X, Li VK, Ding Y, Yang B, Geng J, Lai R, Ding S, Ni M, Zhao R: Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancer. BMC Cancer; 2008;8:44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Right colonic lesions and mucinous carcinoma were not common in MSI carriers.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Genet. 2005 Aug;68(2):137-45 [15996210.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):331-5 [15967110.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Arch Pathol Lab Med. 2005 Nov;129(11):1390-7 [16253017.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]
  • [Cites] Oncology. 2005;69(4):354-62 [16293975.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):951-5 [16490738.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):831-8 [16784982.001]
  • [Cites] Gut. 2006 Dec;55(12):1781-8 [16636019.001]
  • [Cites] Digestion. 2006;74(1):58-67 [17095871.001]
  • [Cites] Clin Genet. 2007 Feb;71(2):158-64 [17250665.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 21;99(4):261-3 [17312298.001]
  • [Cites] Histopathology. 2007 Mar;50(4):453-64 [17448021.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3221-8 [17545526.001]
  • [Cites] J Mol Diagn. 2000 Feb;2(1):20-8 [11272898.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):657-62 [11257096.001]
  • [Cites] J Pathol. 2003 May;200(1):23-31 [12692837.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Dis Colon Rectum. 1991 May;34(5):424-5 [2022152.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1758-62 [9392616.001]
  • [Cites] J Hum Genet. 1998;43(2):143-5 [9621522.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] JAMA. 2005 Apr 27;293(16):1986-94 [15855432.001]
  • [Cites] Curr Gastroenterol Rep. 2005 Oct;7(5):412-20 [16168241.001]
  • (PMID = 18257912.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ PMC2275286
  •  go-up   go-down


63. Gong HL, Wang CB, Zhang GJ, Li CF, Yang XY, Hou HL, Zhang XB: [Clinicopathological analysis and differential diagnosis of primary peritoneal adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Feb 24;89(7):463-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis and differential diagnosis of primary peritoneal adenocarcinoma].
  • OBJECTIVE: To investigate the clinicopathological characteristics and differential diagnosis of primary peritoneal adenocarcinoma.
  • METHODS: The clinico-pathological data of 8 patients with primary peritoneal adenocarcinoma, all female, aged 55.7 (45 - 69), were analyzed retrospectively.
  • Pre-operationally, 6 cases were diagnosed as with ovarian cancer, I case as with malignant mesothelioma, and I as with peritoneal carcinoma.
  • Post-operational pathological examination showed 7 cases of serous papillary adenocarcinoma and one case of mucinous adenocarcinoma.
  • CONCLUSION: A rare malignant tumor arising from the secondary Müllerian system, primary peritoneal adenocarcinoma shares similar histopathological characters with ovary carcinoma, so is easy to be misdiagnosed.
  • Immunohistochemical staining is helpful to the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567094.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


64. Khunamornpong S, Suprasert P, Pojchamarnwiputh S, Na Chiangmai W, Settakorn J, Siriaunkgul S: Primary and metastatic mucinous adenocarcinomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol; 2006 Apr;101(1):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and metastatic mucinous adenocarcinomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality.
  • Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis.
  • Am J Surg Pathol 2003; 27: 985-93 [5]) that classifies mucinous adenocarcinomas of the ovary as primary when they were unilateral > or =10 cm and as metastatic when they were unilateral <10 cm or bilateral.
  • METHODS: Malignant ovarian neoplasms, which were resected in Chiang Mai University Hospital between 1992 and 2003, were histologically reviewed.
  • Mucinous adenocarcinomas involving the ovary were identified.
  • The medical records and radiologic materials were reviewed in correlation with the pathologic features to identify the primary site.
  • RESULTS: There were 74 cases of mucinous adenocarcinomas; 16 were primary ovarian; 52, metastatic; and 6 of indeterminate primary site (primary versus metastatic).
  • Primary mucinous adenocarcinomas had a mean size of 16.4 cm and bilateral involvement in 13%.
  • Metastatic mucinous adenocarcinomas had a mean size of 11.7 cm and bilateral involvement in 77%.
  • Excluding the 6 tumors of indeterminate primary site, the proposed algorithm correctly classified primary and metastatic tumors in 84% of 68 cases.
  • Of 21 unilateral mucinous adenocarcinomas > or =10 cm, 62% were primary ovarian.
  • Of 42 bilateral mucinous adenocarcinomas, 95% were metastatic.
  • CONCLUSION: The algorithm provided high accuracy in the overall prediction of primary and metastatic mucinous adenocarcinomas of the ovary, with major strength in the identification of metastatic tumors by bilaterality or size <10 cm.
  • However, the prediction of primary mucinous adenocarcinomas by unilaterality and size > or =10 cm was less reliable than previously reported.
  • Due to the overlapping features between primary and metastatic tumors and the higher frequency of the latter, the possibility of metastases should always be borne in mind in the evaluation of mucinous adenocarcinomas of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300822.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Schönleben F, Allendorf JD, Qiu W, Li X, Ho DJ, Ciau NT, Fine RL, Chabot JA, Remotti HE, Su GH: Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas; 2008 Mar;36(2):168-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
  • METHODS: To evaluate the mutational status of these genes in intraductal papillary mucinous neoplasm (IPMN)/intraductal papillary mucinous carcinoma (IPMC), EGFR and HER2 were analyzed in 36 IPMN/IPMC, and the results were correlated to the mutational status of the KRAS, BRAF, and PIK3CA genes in the samples.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Neoplasma. 2004;51(2):77-83 [15190415.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1480-3 [15362782.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Pancreas. 1996 May;12(4):362-8 [8740403.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1447-54 [9358771.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7 [15647370.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1642-6 [15753357.001]
  • [Cites] Int J Gastrointest Cancer. 2005;35(2):111-9 [15879625.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4562-7 [15930273.001]
  • [Cites] APMIS. 2005 Oct;113(10):683-7 [16309427.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1441-6 [16533766.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • (PMID = 18376308.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095434-05; United States / NCI NIH HHS / CA / R01 CA109525-05; United States / NCI NIH HHS / CA / R01 CA109525-03; United States / NCI NIH HHS / CA / CA95434; United States / NCI NIH HHS / CA / CA109525-03; United States / NCI NIH HHS / CA / CA109525-04; United States / NCI NIH HHS / CA / R01 CA109525; United States / NCI NIH HHS / CA / CA109525-05; United States / NCI NIH HHS / CA / R01 CA109525-04; United States / NCI NIH HHS / CA / K01 CA095434; United States / NCI NIH HHS / CA / K01 CA095434-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS235133; NLM/ PMC3915029
  •  go-up   go-down


66. Madur B, Shet T, Chinoy R: Cytologic findings in infiltrating micropapillary carcinoma and mucinous carcinomas with micropapillary pattern. Acta Cytol; 2007 Jan-Feb;51(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic findings in infiltrating micropapillary carcinoma and mucinous carcinomas with micropapillary pattern.
  • OBJECTIVE: To examine the observation that some mucinous carcinomas have a micropapillary pattern and are mucinous variants of the highly angioinvasive infiltrating micropapillary carcinomas (IMPC).
  • STUDY DESIGN: We evaluated cytologic findings of 13 IMPC and 55 mucinous carcinomas for comparative features.
  • RESULTS: In mucinous carcinomas, 37 of 50 (74%) had a micropapillary pattern.
  • This group included 27 cases with pure mucinous micropapillary morphology (MUMPC), 8 MUMPC associated with a ductal carcinoma of the IMPC type (MUIDC) and 2 cases of mixed mucinous carcinomas with an MUMPC and a solid variant ofpapillary carcinoma (SVPC) component.
  • On cytology both IMPC and mucinous carcinomas with micropapillary pattern demonstrated the micropapillary pattern, that is, angulated clusters or abortive papillae and ball-like clusters.
  • CONCLUSION: Although IMPC and the MUMPC share the micropapillary pattern on histologic examination, mucin alters the appearances in aspirates.
  • Recognition of this morphologic spectrum will help in understanding the behavior of these tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / pathology. Chemotherapy, Adjuvant. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2007 Jan-Feb;51(1):1-2 [17328486.001]
  • (PMID = 17328491.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Punia RP, Mundi I, Arora K, Dalal A, Mohan H: Primary adenocarcinoma of ureter mimicking pyelonephritis. Urol Ann; 2010 Jan;2(1):42-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of ureter mimicking pyelonephritis.
  • We present a case of primary mucinous adenocarcinoma of the ureter diagnosed as chronic pyelonephritis preoperatively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842259.001).
  • [ISSN] 0974-7834
  • [Journal-full-title] Urology annals
  • [ISO-abbreviation] Urol Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2934591
  • [Keywords] NOTNLM ; Adenocarcinoma / pyelonephritis / ureter
  •  go-up   go-down


68. Ray-Coquard I, Pautier P, Pujade-Lauraine E, Méeus P, Morice P, Treilleux I, Duvillard P, Alexandre J, Lhommé C, Selle F, Guastalla J: [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France]. Bull Cancer; 2010 Jan;97(1):123-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs rares de l'ovaire: stratégies thérapeutiques en 2010, Observatoire francophone des tumeurs rares de l'ovaire et émergence des centres de références.
  • Majorities of the rare ovarian cancers were represented by germ cell tumours and sex cords ovarian tumours with borderline tumours, clear cell carcinoma and mucinous carcinoma and are extremely rare malignant diseases of the ovaries.
  • All together, they represented less than 5% of the adult malignant and non malignant ovarian tumours.
  • Surgery is the same as that for ovarian adenocarcinoma, with one major difference: conservation of reproductive function in women of reproductive age is usual case for this type of tumor.
  • For rare epithelial carcinoma, carboplatin plus paclitaxel remains the standard attitude with a well-known less efficiency than for other epithelial subtypes.
  • Objectives were: to delineate prognostic factors of these very rare diseases, to favour patient inclusion in a clinical trial available online, to provide access to online medical expert forum (disease-related) for complex cases, and finally to demonstrate the impact of these tools on improving medical practice.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / therapy. Adult. Antineoplastic Agents / therapeutic use. Female. France. Humans. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Rare Diseases / pathology. Rare Diseases / therapy. Sarcoma / pathology. Sarcoma / therapy. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20007069.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


69. Perez RO, Habr-Gama A, dos Santos RM, Proscurshim I, Campos FG, Rawet V, Kiss D, Cecconello I: Peritumoral inflammatory infiltrate is not a prognostic factor in distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg; 2007 Nov;11(11):1534-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For this reason, we decided to study the effect of the presence of this pathological finding on disease recurrence and survival.
  • The lack of peritumoral inflammatory response was significantly associated with the presence of mucinous component (13 vs 3%; p = 0.02).
  • Five-year overall survival (91 vs 81%) and disease-free survival (57 vs 48%) were not significantly different between patients with and without peritumoral inflammatory response (p = 0.5 and 0.3, respectively).
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Rectal Neoplasms / mortality. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Humans. Inflammation / pathology. Male. Middle Aged. Neoadjuvant Therapy. Prognosis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Nat Immunol. 2001 Apr;2(4):293-9 [11276199.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1805-13 [10362805.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):438-43 [15719190.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] J Gastrointest Surg. 2006 Dec;10(10):1319-28; discussion 1328-9 [17175450.001]
  • [Cites] J Pathol. 1999 Dec;189(4):487-95 [10629548.001]
  • [Cites] Zentralbl Chir. 2000;125(4):356-64 [10829316.001]
  • [Cites] Dis Colon Rectum. 2004 Jun;47(6):807-17 [15108028.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4302-11 [15381684.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):290-3 [7882795.001]
  • [Cites] Biologicals. 1996 Dec;24(4):329-32 [9088548.001]
  • [Cites] Lancet. 1995 Nov 4;346(8984):1200-1 [7475662.001]
  • [Cites] FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):227-32 [10575133.001]
  • [Cites] Prog Exp Tumor Res. 1970;13:1-27 [4921480.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):411-23 [15875292.001]
  • [Cites] Acta Oncol. 1995;34(1):69-73 [7532422.001]
  • [Cites] Dis Colon Rectum. 2005 Oct;48(10):1868-74 [16175323.001]
  • [Cites] Hum Pathol. 1989 Feb;20(2):159-63 [2562788.001]
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):47-56 [11707870.001]
  • [Cites] Dis Colon Rectum. 1996 Apr;39(4):429-34 [8878504.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2320-8 [9191519.001]
  • [Cites] BMC Cancer. 2001;1:7 [11481031.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8697-705 [16314629.001]
  • [Cites] Eur J Surg. 1999 Jun;165(6):588-92 [10433145.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):875-87 [12847360.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s123-5 [15655594.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1264-8 [3675190.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Drug Saf. 2000 Aug;23(2):101-13 [10945373.001]
  • [Cites] J Pathol. 1997 Jul;182(3):318-24 [9349235.001]
  • [Cites] Lancet. 1987 Jun 6;1(8545):1303-6 [2884421.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):968-76 [8780533.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):427-37 [15967836.001]
  • [Cites] J Infect Dis. 2002 Sep 1;186(5):606-16 [12195347.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2069-76 [14959849.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1087-96 [9749491.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8 [15383798.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] Cancer Detect Prev. 1986;9(3-4):359-64 [3488807.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1703-7 [15532809.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17 ):5564-72 [14500396.001]
  • (PMID = 17786526.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Celis JE, Gromova I, Gromov P, Moreira JM, Cabezón T, Friis E, Rank F: Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett; 2006 May 22;580(12):2935-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
  • Breast cancer is a heterogeneous disease that encompasses a wide range of histopathological types including: invasive ductal carcinoma, lobular carcinoma, medullary carcinoma, mucinous carcinoma, tubular carcinoma, and apocrine carcinoma among others.
  • Pure apocrine carcinomas represent about 0.5% of all invasive breast cancers according to the Danish Breast Cancer Cooperative Group Registry, and despite the fact that they are morphologically distinct from other breast lesions, there are at present no standard molecular criteria available for their diagnosis.
  • In addition, the relationship between benign apocrine changes and breast carcinoma is unclear and has been a matter of discussion for many years.
  • These biomarkers in combination with proteins found to be characteristically upregulated in pure apocrine carcinomas (psoriasin, S100A9, and p53) provide a protein expression signature distinctive for benign apocrine metaplasias and apocrine cystic lesions.
  • These studies have also presented compelling evidence for a direct link, through the expression of the prostaglandin degrading enzyme 15-PGDH, between early apocrine lesions and pure apocrine carcinomas.
  • Moreover, specific antibodies against the components of the expression signature have identified precursor lesions in the linear histological progression to apocrine carcinoma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631754.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 85
  •  go-up   go-down


71. Popnikolov NK, Cavone SM, Schultz PM, Garcia FU: Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. Mod Pathol; 2005 Dec;18(12):1535-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical staining for p75NTR was performed on paraffin sections of 122 malignant breast lesions, 28 benign lesions and the adjacent normal breast tissue.
  • The staining pattern was compared to those of myosin heavy chain and p63. p75NTR immunostain was consistently positive and compatible with p63 and myosin immunoreactivity in the myoepithelial cells of the normal mammary gland, benign breast lesions (six usual ductal hyperplasias, six specimens with sclerosing adenosis, eight intraductal papillomas, six fibroadenomas), and carcinoma in situ (18 ductal carcinomas in situ, two noninvasive papillary carcinomas, two lobular carcinomas in situ).
  • Four of 64 invasive ductal carcinomas (6%) and all metaplastic carcinomas (n = 3, 100%) showed a variable degree of p75(NTR) positivity.
  • No p75NTR expression was found in the malignant cells in all in situ carcinomas, invasive lobular carcinomas (n = 11), tubular carcinomas (n = 10), invasive papillary carcinomas (n = 6), mucinous carcinomas (n = 4), and medullary carcinomas (n = 2).
  • Our study shows that p75NTR is a useful marker for breast myoepithelial cells and can be used to rule out invasive disease as well as to evaluate difficult for diagnosis sclerosing lesions.
  • Our data suggest a role of neurotrophins in the development of fibroepithelial breast tumors and some of the breast carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology. Muscle, Smooth / pathology. Receptor, Nerve Growth Factor / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Myosin Heavy Chains / metabolism. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258511.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


72. Min BS, Kim NK, Ko YT, Baek SH, Lee KY, Sohn SK, Cho CH, Kang DR: Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study. Hepatogastroenterology; 2009 Jul-Aug;56(93):984-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study.
  • BACKGROUND/AIMS: Primary colorectal signet-ring cell carcinoma (SRC) is a rare type of mucin-containing adenocarcinoma and little information exists about its clinicopathological features.
  • METHODS: The clinicopathological features of 27 patients with primary colorectal SRC were compared with non-signet-ring cell mucinous carcinoma (MC) and non-mucinous adenocarcinoma (NMC).
  • In stage II and III, SRC was found to be associated with a worse cancer-specific survival and a higher systemic recurrence rates than either NMC or MC.
  • CONCLUSIONS: Primary colorectal SRC has distinctive clinicopathological features and is associated with a poorer prognosis than the other histological subtypes.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology


73. Schmid KW: [Problem areas of tumour classifications--thyroid carcinomas]. Verh Dtsch Ges Pathol; 2007;91:57-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Problem areas of tumour classifications--thyroid carcinomas].
  • Thyroid carcinoma has been traditionally subdivided into the four major groups papillary, follicular, medullary, and anaplastic carcinoma.
  • The WHO classification of thyroid tumours, published in 2004, has added to these four tumour groups the entity of poorly differentiated carcinoma as well as a broad variety of rare thyroid malignancies.
  • Another important change concerns the histological hallmarks of papillary carcinoma, the diagnosis of which is now exclusively dependent on characteristic nuclear features.
  • The aim of the present paper is to highlight diagnostic problems particularly caused by the alteration introduced onto the WHO classification, This includes a proposal of a more systematic thyroid carcinoma classification based on the histogenetic differentiation (follicular cell differentiation.
  • C cell differentiation, rare carcinomas) and tumour grading of carcinomas with follicular cell differentiation (differentiated, poorly differentiated and anaplastic carcinomas) as well as commentaries on the diagnosis of papillary carcinoma, poorly differentiated carcinoma, and rare types of thyroid carcinoma (squamous cell carcinoma, mucoepidermoid carcinoma, sclerosing mucoepidermoid carcinoma with eosinophilia, mucinous carcinoma, SETTLE, and CASTLE).
  • [MeSH-major] Carcinoma / classification. Thyroid Neoplasms / classification
  • [MeSH-minor] Carcinoma, Papillary / classification. Carcinoma, Papillary / pathology. Humans. World Health Organization

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18314596.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 37
  •  go-up   go-down


74. Vodovnik A: Primary mucinous carcinoma of the skin. J Cutan Pathol; 2006 Jan;33(1):61-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous carcinoma of the skin.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Axilla. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Humans. Male. Middle Aged. Mucins / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441416.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


75. Molavi D, Argani P: Distinguishing benign dissecting mucin (stromal mucin pools) from invasive mucinous carcinoma. Adv Anat Pathol; 2008 Jan;15(1):1-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing benign dissecting mucin (stromal mucin pools) from invasive mucinous carcinoma.
  • Mucin dissecting stroma suggests the presence of an invasive mucinous (colloid) carcinoma.
  • However, in virtually every organ in which invasive mucinous carcinoma exists, there exist benign mimickers associated with dissecting mucin.
  • This article reviews diagnostic criteria for the differential diagnosis of mucinous lesions of the breast, pancreas, biliary tract, colon, appendix, and bladder, emphasizing practical points, which we find helpful in daily diagnostic surgical pathology practice.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Epithelial Cells / pathology. Mucins
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Diagnosis, Differential. Female. Humans. Male. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156808.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 88843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 51
  •  go-up   go-down


76. Chang YW, Kwon KH, Lee DW: Synchronous bilateral mucinous carcinoma of the breast: case report. Clin Imaging; 2009 Jan-Feb;33(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous bilateral mucinous carcinoma of the breast: case report.
  • A mucinous carcinoma of the breast is a well-differentiated rare histological type of invasive ductal carcinoma, having a lower frequency of metastasis to an axillary lymph node and a better survival rate.
  • Bilateral breast cancer has an overall incidence of 4% to 20% in patients with primary operable breast cancer.
  • Few reports exist in the clinical literature characterizing a synchronous bilateral mucinous carcinoma of the breast.
  • We report the characteristic imaging findings of a bilateral mucinous carcinoma of the breast.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Mammography / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135933.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Espinel J, Pinedo E, Rascarachi G: Endoscopic mucosal resection with a multiband ligator for the treatment of Barrett s high-grade dysplasia and early gastric cancer. Rev Esp Enferm Dig; 2009 Jun;101(6):403-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection with a multiband ligator for the treatment of Barrett s high-grade dysplasia and early gastric cancer.
  • The objective of this study was to evaluate the efficacy and safety of EMR with a ML device in the treatment of Barrett s high-grade dysplasia and early gastric cancer.
  • EMR was performed with a multiband ligator in order to create a pseudopolyp and then permit snare polypectomy of flat mucosal lesions.
  • The histology of the EMR specimens confirmed a moderately differentiated adenocarcinoma with submucosal infiltration (1 patient) and BHGD (3 patients).
  • The histology of EMR specimens confirmed a mucinous adenocarcinoma with submucosal infiltration (1 patient), EGC (2 patients), and HGD (1 patient).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19630463.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


78. Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS: Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol; 2005 Apr;97(1):110-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Results of a recent study on human ovarian cancer cell lines indicated that overexpression of dihydrodiol dehydrogenase (DDH) was associated with resistance to cisplatin and disease progression.
  • All patients underwent primary debulking surgery, followed with six cycles of cisplatin-based chemotherapy.
  • Of interest, the clear cell adenocarcinoma revealed DDH overexpression (75%) and mucinous adenocarcinoma revealed low DDH expression (16.7%), although DDH expression did not show any significant variation according to different histotypes.
  • CONCLUSIONS: DDH is expressed in a high percentage of primary ovarian tumors and its expression may be associated with cisplatin-based chemotherapy resistance.
  • The possible prognostic role of DDH in ovarian carcinoma deserves further study.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790446.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Messenger; EC 1.- / Oxidoreductases; EC 1.3.1.20 / trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


79. Bossard C, Denis MG, Bézieau S, Bach-Ngohou K, Bourreille A, Laboisse CL, Mosnier JF: Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. Oncol Rep; 2007 Nov;18(5):1093-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis.
  • The purpose of this study is to identify colorectal serrated lesions in the inflammatory mucosa of inflammatory bowel disease (IBD), to characterize their molecular status based on BRAF and KRAS mutations, mismatch-repair (MMR) deficiency and microsatellite instability (MSI), and to verify that these molecular alterations are specific to the 'serrated neoplasia pathway' in IBD.
  • Neoplastic lesions from 36 patients with IBD were reviewed retrospectively, including 13 adenocarcinomas (1 mucinous and 12 conventional), 28 dysplasias [1 traditional serrated adenoma (TSA) and 27 conventional adenomas] and 1 hyperplastic polyp (HP).
  • The mucinous adenocarcinoma, close to the TSA, exhibited the BRAF mutation and MSI with loss of hMLH1.
  • Serrated lesions exist in the inflammatory mucosa of IBD and are associated with a characteristic molecular profile, i.e. the appearance of the BRAF mutation as early as the hyperplastic polyp stage followed by MSI at the carcinoma stage.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. CpG Islands / genetics. DNA Methylation. DNA Mismatch Repair. DNA, Neoplasm / analysis. Humans. Microsatellite Instability. Mutation. Phenotype. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Retrospective Studies. Signal Transduction


80. Ivan D, Nash JW, Prieto VG, Calonje E, Lyle S, Diwan AH, Lazar AJ: Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J Cutan Pathol; 2007 Jun;34(6):474-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin.
  • Others and we have shown the value of p63 in distinguishing primary adnexal tumors from visceral adenocarcinomas metastatic to skin.
  • We now investigate the pattern of p63 expression in metastases from skin adnexal carcinomas and their cognate primaries and evaluate p63 expression in a larger case series of malignant cutaneous adnexal neoplasms.
  • Immunohistochemical analysis for p63 was performed on 13 metastases of adnexal carcinomas and their corresponding primary tumors.
  • Twenty visceral metastatic adenocarcinomas to the skin and 7 primary mucinous carcinomas with cutaneous or visceral origin were compared.
  • The majority (90.9%) of primary adnexal tumors strongly expressed p63 and their metastases labeled similar to their cognate primary tumors.
  • With one exception, primary or metastatic mucinous carcinomas did not express p63.
  • Metastases from two apocrine carcinomas lacked p63 expression.
  • All other cutaneous metastases from internal adenocarcinomas were negative for p63.
  • Analysis of p63 expression may assist in the differential diagnosis of primary adnexal carcinomas versus metastatic visceral adenocarcinomas to the skin.
  • Metastases from adnexal carcinomas generally retain p63 expression similar to their associated primary tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Skin Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Retrospective Studies. Transcription Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2008 Jul;35(7):692-3 [18312438.001]
  • (PMID = 17518775.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


81. Nolan L, Eccles D, Cross E, Crawford G, Beck N, Bateman A, Ottensmeier C: First case report of Muir-Torre syndrome associated with non-small cell lung cancer. Fam Cancer; 2009;8(4):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The eponymous Muir-Torre syndrome (MTS) is a clinical variant of hereditary non polyposis colorectal cancer, and is defined as an autosomal dominant condition with simultaneous sebaceous neoplasms of the skin and visceral malignant disease resulting from germline mutations in the DNA mismatch repair (MMR) genes.
  • Other clearly associated tumours include endometrial adenocarcinomas, urothelial transitional cell carcinomas, upper gastrointestinal adenocarcinomas, sebaceous adenomas and ovarian (often mucinous) carcinomas.
  • Here we report the first recorded case of adenocarcinoma of the lung with loss of MMR gene function to be identified in a patient with MTS.
  • The MMR deficient lung tumour demonstrated less aggressive clinical behaviour compared with a synchronous MMR proficient lung adenocarcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Muir-Torre Syndrome / genetics


82. La Rosa S, Franzi F, Marchet S, Finzi G, Clerici M, Vigetti D, Chiaravalli AM, Sessa F, Capella C: The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch; 2009 Feb;454(2):133-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.
  • Acinar cell carcinoma (ACC) is a rare pancreatic cancer which may be difficult to distinguish from other solid nonadenocarcinoma tumors.
  • The diagnosis depends on the demonstration of acinar differentiation, obtained with antibodies recognizing various pancreatic enzymes that, although specific, show different sensitivity.
  • We investigated the usefulness of a C-terminal BCL10 monoclonal antibody in the diagnosis of ACCs.
  • We examined normal pancreases and different pancreatic tumors including ACCs, mixed acinar-endocrine carcinomas, ductal adenocarcinomas, mucinous, serous, solid pseudopapillary, and endocrine neoplasms.
  • In addition, various normal tissues and cases of pancreatic metaplasia of the gastroesophageal mucosa, cases of ectopic pancreas, gastrointestinal endocrine tumors, salivary and breast acinic cell carcinomas, gastric adenocarcinomas with and without acinar differentiation, and hepatocellular carcinomas were studied.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Antibodies, Monoclonal / immunology. Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / diagnosis. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 1998 Feb 1;329 ( Pt 3):675-9 [9445398.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):104-8 [10839610.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):739-47 [3542187.001]
  • [Cites] FEBS Lett. 1991 Jan 28;278(2):190-4 [1991511.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):649-54 [16865281.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):248-54 [15517368.001]
  • [Cites] Differentiation. 1992 Sep;51(1):55-60 [1451962.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):869-73 [9224759.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Sep 15;155(2):950-5 [3421974.001]
  • [Cites] Eur J Biochem. 1990 Sep 11;192(2):543-50 [1698625.001]
  • [Cites] Biochim Biophys Acta. 1995 Oct 17;1272(2):69-72 [7548236.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Int J Pancreatol. 1989 Sep;5(2):123-34 [2689525.001]
  • [Cites] Virchows Arch. 2007 Aug;451 Suppl 1:S61-9 [17684764.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] J Clin Invest. 1990 Apr;85(4):1221-6 [2318975.001]
  • [Cites] Biochim Biophys Acta. 1978 Nov 10;527(1):142-9 [718955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12641-6 [9770539.001]
  • [Cites] APMIS. 1995 Jan;103(1):69-78 [7695893.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):363-70 [17325477.001]
  • [Cites] Genomics. 1993 Aug;17(2):416-22 [7691717.001]
  • (PMID = 19066953.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / BCL10 protein, human; 0 / Biomarkers, Tumor; EC 3.1.1.1 / Carboxylesterase
  •  go-up   go-down


83. Arfaoui-Toumi A, Kria-Ben Mahmoud L, Ben Hmida M, Khalfallah MT, Regaya-Mzabi S, Bouraoui S: Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian patients). Bull Cancer; 2010 Feb;97(2):E1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a comparative immunohistochemical analysis of galectin-3 expression in term of intensity and distribution in normal mucosa, in primary tumor and in metastasis from 200 patients with colorectal cancer selected among 325 cases.
  • We also compared the galectin-3 staining according to the histological subtype (mucinous vs non mucinous), tumoral differentiation and stage of tumor.
  • We showed a strong and diffuse positive staining of galectin-3 in both adjacent and distanced normal mucosa, in well differentiated adenocarcinoma and in metastasis.
  • We also observed a loss of this protein in adenocarcinoma with mucinous component < 50%, where the positive staining was limited only to the well differentiated areas of tumor.
  • These data suggest that galectin-3 play an important role in colorectal cancer progression concerning the non mucinous carcinoma and can be used as a prognostic factor to predict poor outcome of patients.
  • In mucinous subtype, galectin-3 might be implicated in one or many step of its genesis perhaps through the control of cellular adhesion and interaction with mucin produced.
  • Adenocarcinoma with mucinous component <50% would be integrate to mucinous carcinoma, not to non mucinous ones.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Colorectal Neoplasms / metabolism. Galectin 3 / metabolism. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 3.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20080461.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Galectin 3; 0 / Neoplasm Proteins
  •  go-up   go-down


84. Bu XD, Li N, Tian XQ, Li L, Wang JS, Yu XJ, Huang PL: Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma. World J Gastroenterol; 2010 Aug 28;16(32):4089-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma.
  • AIM: To study the expression profiles of MUC2 and MUC5AC in tumorigenesis of colorectal carcinoma and in its different pathologic types.
  • Six samples of normal mucosa (NM), 12 samples of hyperplastic polyp (HP), 15 samples of tubular adenoma with low-grade dysplasia (LGD), 14 samples of tubular adenoma with high-grade dysplasia (HGD), 26 samples of conventional colorectal adenocarcinoma (CCA), 15 samples of mucinous carcinoma (MC), and 8 samples of signet-ring cell carcinoma (SRCC) were collected.
  • The transformation process in MC and SRCC may be different from that in the traditional adenoma-carcinoma sequence.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Disease Progression. Mucin 5AC / metabolism. Mucin-2 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol. 1998 Nov-Dec;7(3-4):115-23 [10677163.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1909-16 [10815915.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4017-25 [11051251.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Jan;24(1):22-29 [11152646.001]
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Cancer Lett. 2001 Jul 10;168(1):71-80 [11368880.001]
  • [Cites] J Pathol. 2001 Oct;195(3):327-35 [11673830.001]
  • [Cites] Science. 2002 Mar 1;295(5560):1726-9 [11872843.001]
  • [Cites] Pathol Int. 2002 Jul;52(7):470-7 [12167106.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48270-5 [12374798.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Pathol Res Pract. 2004;200(5):371-7 [15239345.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):560-4 [8813954.001]
  • [Cites] J Pathol. 1997 Aug;182(4):380-4 [9306957.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):210-8 [9935202.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):59-67 [15603855.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1305-10 [15857840.001]
  • [Cites] World J Gastroenterol. 2005 Aug 28;11(32):4939-46 [16124042.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2035-47 [16206296.001]
  • [Cites] BMC Gastroenterol. 2006;6:4 [16409634.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1765(2):189-222 [16487661.001]
  • [Cites] Gene. 2006 May 24;373:28-34 [16500040.001]
  • [Cites] Histopathology. 2006 Jul;49(1):35-44 [16842244.001]
  • [Cites] J Pathol. 2007 Jul;212(3):278-86 [17471475.001]
  • [Cites] World J Gastroenterol. 2007 Sep 7;13(33):4437-44 [17724798.001]
  • [Cites] Glycobiology. 2008 Jan;18(1):74-83 [17977904.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):577-84 [17916404.001]
  • [Cites] Int J Colorectal Dis. 2008 Aug;23(8):757-65 [18458918.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Dec 19;377(3):763-8 [18957283.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(1):33-47 [18938071.001]
  • [Cites] Gastroenterology. 2010 Jun;138(6):2073-2087.e3 [20420947.001]
  • (PMID = 20731025.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucin 5AC; 0 / Mucin-2
  • [Other-IDs] NLM/ PMC2928465
  •  go-up   go-down


85. Symons NR, Guenther T, Gupta A, Northover JM: Para-neorectal mucinous adenocarcinoma following childhood pull-through procedure for imperforate anus. Colorectal Dis; 2010 Mar;12(3):262-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Para-neorectal mucinous adenocarcinoma following childhood pull-through procedure for imperforate anus.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Anus, Imperforate / surgery. Digestive System Surgical Procedures. Postoperative Complications / pathology. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Imperforate anus.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207703.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Hart WR: Mucinous tumors of the ovary: a review. Int J Gynecol Pathol; 2005 Jan;24(1):4-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous tumors of the ovary: a review.
  • Mucinous ovarian tumors are among the most difficult ovarian neoplasms for surgical pathologists to interpret.
  • Approximately 20% of primary ovarian mucinous tumors are borderline tumors, noninvasive (intraglandular; intraepithelial) carcinomas, or invasive carcinomas; the remainder are cystadenomas.
  • Their frequently heterogeneous composition with coexisting elements of cystadenoma, stromal microinvasion, noninvasive carcinoma, and invasive carcinoma requires careful gross examination and extensive sampling of the tumors.
  • The inherent glandular complexity of proliferating mucinous tumors complicates recognition of stromal invasion.
  • Some mucinous carcinomas with expansile (confluent) invasion may be very difficult to discriminate from extensive noninvasive carcinoma.
  • Interobserver reproducibility probably requires use of an arbitrary minimum size criterion for the diagnosis of expansile invasion.
  • Primary invasive carcinomas with an infiltrative growth pattern are less common.
  • Rarely, distinct mural nodules of reactive or neoplastic type are found in the cystic wall of a mucinous tumor.
  • Pseudomyxoma peritonei almost never results from a ruptured primary ovarian mucinous neoplasm, but often produces secondary borderline-like ovarian tumors with prominent pseudomyxoma ovarii.
  • Prognosis of mucinous tumors is highly dependent on stage and histologic composition.
  • Borderline tumors, noninvasive carcinomas, microinvasive tumors, and invasive carcinomas with an expansile growth pattern are generally stage I and have an excellent prognosis with only occasional examples of metastatic spread.
  • Invasive carcinomas with an infiltrative growth pattern are more aggressive, accounting for almost all high-stage mucinous tumors, and are responsible for most deaths caused by tumor.
  • A high index of suspicion that a mucinous tumor is actually a metastasis from another organ is required by pathologists and gynecologists to prevent misdiagnosis of a metastatic neoplasm as a primary ovarian tumor.
  • Secondary mucinous tumors are significantly more often bilateral, <10 cm in maximal dimension, and of high stage.
  • Numerous immunohistochemical stains proposed to aid in the differential diagnosis of primary vs. secondary mucinous tumors also are reviewed.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Carcinoma in Situ / pathology. Female. Humans. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Metastasis. Peritoneal Neoplasms / pathology. Prognosis. Pseudomyxoma Peritonei / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626914.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 88
  •  go-up   go-down


87. Işin Doğan Ekici A, Küçükali T, Coşkun Salman M, Ayhan A: Triple simultaneous primary gynecological malignancies in a 56-year-old patient. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1947-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple simultaneous primary gynecological malignancies in a 56-year-old patient.
  • The occurrence of double simultaneous primary cancers is common.
  • However, the occurrence of synchronous primary triple gynecological malignancies is an extremely rare event.
  • In this report, the clinical and pathologic findings of a 56-year-old female patient with synchronous triple primary gynecological cancers including well-differentiated ovarian mucinous cystadenocarcinoma, well-differentiated endometrial endometrioid adenocarcinoma, and uterine leiomyosarcoma were presented.
  • Synchronous primary, well-differentiated endometrial endometrioid adenocarcinoma and leiomyosarcoma of uterus without any ovarian neoplasm has only been once described in the English literature.
  • To our knowledge, the presented patient is the first case in aspect of accompanying ovarian mucinous adenocarcinoma to endometrial endometrioid adenocarcinoma and leiomyosarcoma of uterus.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / pathology. Leiomyosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009998.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Moryl N, Coyle N, Foley KM: Managing an acute pain crisis in a patient with advanced cancer: "this is as much of a crisis as a code". JAMA; 2008 Mar 26;299(12):1457-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the case of Mr X, a 33-year-old man with advanced metastatic mucinous adenocarcinoma of the appendix and "15 out of 10" pain, we explore the issues of acute pain and its management.
  • Our management strategy focuses on making a pain diagnosis, differentiating reversible from intractable causes of pain, and making decisions about further workup; selecting the opioid and monitoring and treating opioid adverse effects; titrating and rotating opioid and coanalgesics; consulting experts to treat a pain crisis as quickly as possible to prevent unnecessary suffering; and co-opting the available institutional resources.

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. METHADONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] JAMA. 2009 Mar 25;301(12):1230. Dosage error in article text
  • [ErratumIn] JAMA. 2008 May 14;299(18):2150. Dosage error in article text
  • (PMID = 18364488.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Case Reports; Clinical Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Anesthesia; 0 / Analgesics, Opioid; 0 / Anesthetics, Dissociative; 0 / Anti-Anxiety Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Glucocorticoids; 12794-10-4 / Benzodiazepines; UC6VBE7V1Z / Methadone
  •  go-up   go-down


89. Marci V, Volante M, Cappia S, Righi L, Novello C, Scagliotti GV, Brambilla E, Papotti M: Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Arch; 2007 Sep;451(3):729-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma.
  • The 2004 WHO classification of lung tumours recognised basaloid carcinoma as a variant of squamous and large cell carcinoma.
  • We report a unique case of primary pulmonary adenocarcinoma with a basaloid component.
  • The patient is disease-free 13 months after diagnosis.
  • Histologically, an invasive carcinoma having a glandular and a solid component was observed.
  • The former was an adenocarcinoma with mucus containing spaces lined by columnar mucinous cells and basaloid cells.
  • The solid component was an organoid proliferation of basaloid-type cells, as in cutaneous basal cell carcinoma.
  • Basaloid cells, but not mucinous cells, were immunoreactive for high molecular weight cytokeratins (CK), CK 7 and, focally, for TTF-1.
  • (1) The solid areas resemble a conventional basaloid carcinoma, except for the presence of small mucin-containing spaces. (2) The mucinous adenocarcinoma areas contain two layers of columnar and basaloid cells. (3) Both components are neoplastic based on cell morphology, invasive properties and phenotypic profile.
  • These findings indicate that a basaloid variant of adenocarcinoma is also existing in the spectrum of basaloid carcinomas of the lung.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell. Humans. Keratins / analysis. Male. Mucins / analysis. Neoplasm Invasiveness. Phenotype. World Health Organization


90. Pryczynicz A, Guzińska-Ustymowicz K, Chang XJ, Kiśluk J, Kemona A: PTP4A3 (PRL-3) expression correlate with lymphatic metastases in gastric cancer. Folia Histochem Cytobiol; 2010 Dec;48(4):632-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atotal of 71 patients with gastric carcinomas were divided according to Lauren's, Goseki's, Bormann's and Kubo's classifications.
  • The expression of the protein was associated more with the poorly-differentiated mucoid carcinoma and diffused-type carcinoma (58% of cases).
  • We demonstrated a statistically significant correlation between local lymph node involvement and positive expression of PTP4A3 in the primary tumour (p=0.0000).
  • The current study seems to prove that PTP4A3 may have a significant impact on the lymphatic spread of gastric carcinoma.
  • The protein expression is also significantly associated with gastric carcinomas having a worse prognosis, although patients' survival rate showed lack of correlation with PTP4A3 expression.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21478108.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


91. Minakawa K, Oka K, Masuda A, Yonekawa N, Kashimura J, Nihei T: Extensive endothelial replacement by tumor cells in the portal system: an autopsy case of intrahepatic cholangiocarcinoma. Pathol Int; 2010 Aug;60(8):591-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An autopsy case of intrahepatic cholangiocarcinoma (ICC) with a peculiar form of extensive portal invasion is reported here.
  • These tumors were well-differentiated adenocarcinomas with partial mucinous carcinoma morphology.
  • Surprisingly, portal veins contained mucinous fluid and the inner surface was lined with a single layer of tumor cells but not endothelial cells.
  • Invasion of carcinoma into the tissue outside the blood vessels was hardly observed in organs other than the liver.
  • This form of extensive invasion of the tumor, termed intimal carcinoma spreading, caused complete obstruction of the portal system.

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618738.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


92. Kondo T, Hashi A, Murata S, Nakazawa T, Yuminamochi T, Nara M, Hoshi K, Katoh R: Endocervical adenocarcinomas associated with lobular endocervical glandular hyperplasia: a report of four cases with histochemical and immunohistochemical analyses. Mod Pathol; 2005 Sep;18(9):1199-210
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas associated with lobular endocervical glandular hyperplasia: a report of four cases with histochemical and immunohistochemical analyses.
  • We report on four cases of endocervical adenocarcinoma associated with lobular endocervical glandular hyperplasia using histochemical and immunohistochemical analyses.
  • Cytological examinations of the cervical smears revealed adenocarcinoma cells and benign-looking glandular cells with intracytoplasmic golden-yellow mucin in all cases.
  • From surgical specimens, three tumors were diagnosed as mucinous adenocarcinoma and one was adenocarcinoma in situ.
  • All adenocarcinomas were located proximally on the cervix, and did not involve the transformation zone.
  • Adjacent to carcinoma tissues in the cervix, lobular endocervical glandular hyperplasia was detected.
  • The cells of lobular endocervical glandular hyperplasia were dominantly positive with neutral mucin, and immunohistochemistry revealed that these cells had prominent pyloric gland mucin (HIK1083).
  • Focal immunopositivity for pyloric mucin was also observed in three adenocarcinomas.
  • Either CEA or p53 were immunopositive in all adenocarcinomas and negative in the tissues of lobular endocervical glandular hyperplasia.
  • Histopathological features of the present cases suggest that some endocervical adenocarcinomas may originate from lobular endocervical glandular hyperplasia.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Hyperplasia / complications. Hyperplasia / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Middle Aged. Mucins / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology


93. Mizuta Y, Mizuta N, Sakaguchi K, Hachimine Y, Sawai K, Urasaki K, Yasukawa S, Nakajima H: A case of non-metastatic giant mucinous carcinoma of the breast. Breast Cancer; 2005;12(4):337-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of non-metastatic giant mucinous carcinoma of the breast.
  • A surgically resected case of giant mucinous carcinoma of the breast that had remained untreated for 2 years is reported.
  • A 64-year-old postmenopausal woman presented with a large right breast mass (17.4 x 16.5 x 14.5 cm).
  • Mucinous carcinoma was diagnosed by core needle biopsy and she underwent right modified radical mastectomy with a free skin graft.
  • Although several reports have suggested that pure mucinous carcinoma of the breast has a favorable prognosis, we need to follow this case until the clinical behavior and the outcome become clear.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Breast Neoplasms / pathology. Breast Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Disease-Free Survival. Female. Humans. Mastectomy, Modified Radical. Middle Aged. Postmenopause. Prognosis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286917.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


94. Yuen S, Uematsu T, Kasami M, Tanaka K, Kimura K, Sanuki J, Uchida Y, Furukawa H: Breast carcinomas with strong high-signal intensity on T2-weighted MR images: pathological characteristics and differential diagnosis. J Magn Reson Imaging; 2007 Mar;25(3):502-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinomas with strong high-signal intensity on T2-weighted MR images: pathological characteristics and differential diagnosis.
  • PURPOSE: To investigate the histopathological characteristics of breast carcinomas with strong high-signal intensity (SHi) on T2-weighted (T2W) MR images (T2-SHi), and discuss the differential diagnosis between T2-SHi breast carcinomas and T2-SHi fibroadenomas.
  • MATERIALS AND METHODS: Thirty of 480 breast carcinomas examined by MRI were defined as tumors with T2-SHi (defined as homogeneous higher signal intensity (SI) compared to surrounding normal breast tissue on fat-suppressed T2W imaging (T2WI).
  • They included eight mucinous and 22 nonmucinous carcinomas.
  • The histopathological characteristics of T2-SHi breast carcinomas, their signal-to-noise ratios (SNRs) on T2WI, contrast-enhancement patterns, and morphology were compared with those of 22 non-T2-SHi breast carcinomas and 19 T2-SHi fibroadenomas.
  • RESULTS: In nonmucinous carcinomas T2-SHi was attributable to a mixture of background matrix, a higher proportion of cells than stroma, abundant cytoplasm, edematous stroma, and hemorrhage.
  • The significantly high SNR (mean = 75) and enhancing internal septations seen in mucinous carcinomas, and the washout phenomenon, irregular border, absence of internal septation, and rim enhancement seen in nonmucinous carcinomas provide useful information for differentiating these tumors from T2-SHi fibroadenomas.
  • CONCLUSION: A mixture of several histopathological characteristics was associated with T2-SHi breast carcinomas.
  • The combined information from T2WI and contrast-enhanced (CE) imaging may help distinguish T2-SHi breast carcinomas from T2-SHi fibroadenomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Breast / pathology. Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Fibroadenoma / diagnosis. Magnetic Resonance Imaging / methods. Signal Processing, Computer-Assisted
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Middle Aged. Observer Variation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326093.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


95. Otsuki Y, Yamada M, Shimizu S, Suwa K, Yoshida M, Tanioka F, Ogawa H, Nasuno H, Serizawa A, Kobayashi H: Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases. Pathol Int; 2007 Jul;57(7):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases.
  • The purpose of the present paper was to evaluate the clinicopathological and biological features of 20 Japanese patients with solid-papillary carcinoma of the breast (SPC) or SPC associated with invasive breast cancer.
  • The mean disease-free interval was 4 years 11 months.
  • Histological types of invasive cancers were mucinous carcinoma in five cases and neuroendocrine cell carcinoma in 10 cases.
  • These results indicate that SPC is a potential precursor lesion for neuroendocrine carcinoma as well as mucinous carcinoma.
  • When all the cases were classified and analyzed according to both the 2002 tumor node metastasis (TNM) classification system and the Nottingham histological grade, SPC patients, even those with invasive cancers, seemed to have longer disease-free survival compared to patients with the other invasive breast cancers of matching grade and stage.
  • Clinicopathologically, SPC could be regarded as a separate type of ductal carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / chemistry. Carcinoma, Neuroendocrine / classification. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587241.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


96. Chun EJ, Lee HJ, Kang WJ, Kim KG, Goo JM, Park CM, Lee CH: Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT. Lung Cancer; 2009 Aug;65(2):180-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: (18)F-FDG PET/CT has been used to differentiate malignant solid lung nodules from benign nodules.
  • METHODS: A total of 68 GGNs in 45 patients (M:F=24:21; mean age, 61) fulfilled the following criteria: (a) nodules composed of >/=50% ground-glass opacity, (b) patients who underwent integrated PET/CT within 1 week following dedicated chest CT, (c) definitive diagnosis determined by pathological specimen or at least 9 months of follow-up, and (d) lesions >/=10mm in diameter.
  • 36 malignant GGNs were pathologically proved as adenocarcinoma (n=20), bronchioloalveolar carcinoma (n=11), low-grade lymphoma (n=3), metastatic mucinous adenocarcinoma (n=1) and unknown low-grade malignancy (n=1).
  • CONCLUSION: The part-solid nodules with positive FDG-PET could be inflammatory nodules rather than malignant nodules.
  • This is a quite paradoxical result when considering the basic knowledge that malignant pulmonary nodules have higher glucose metabolism.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155090.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


97. Khoury T, Tan D, Wang J, Intengan M, Yang J, Alrawi S, Yan P, Byrd JC: Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma. BMC Clin Pathol; 2006;6:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma.
  • BACKGROUND: Distinguishing endocervical adenocarcinoma (ECA) from endometrial mucinous adenocarcinoma (EMMA) is clinically significant in view of the differences in their management and prognosis.
  • In this study, we used a panel of tumor markers to determine their ability to distinguish between primary endocervical adenocarcinoma and primary endometrial mucinous adenocarcinoma.
  • CONCLUSION: A panel of immunohistochemical markers including MUC1, p16, ER, PR, and vimentin is recommended, when there is morphological and clinical doubt as to the primary site of endocervical or endometrial origin.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Reprod. 2001 Feb;64(2):590-601 [11159362.001]
  • [Cites] Pathol Annu. 1993;28 Pt 1:329-53 [7677929.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):1-3 [11781515.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):4-10 [11781516.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Trends Biochem Sci. 2002 Mar;27(3):126-31 [11893509.001]
  • [Cites] Histopathology. 2002 Jan;40(1):92-100 [11903603.001]
  • [Cites] Histopathology. 2002 Oct;41(4):313-21 [12383213.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):180-8 [14657952.001]
  • [Cites] Pathol Res Pract. 1993 Sep;189(8):862-6 [8302707.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):172-7 [8617459.001]
  • [Cites] Biol Reprod. 1997 Apr;56(4):999-1011 [9096884.001]
  • [Cites] Lancet. 1979 Dec 1;2(8153):1159-60 [91890.001]
  • [Cites] Biol Reprod. 1997 Aug;57(2):468-77 [9241065.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):383-9 [9563789.001]
  • [Cites] Histopathology. 1998 Mar;32(3):257-63 [9568512.001]
  • [Cites] Hum Reprod Update. 1998 Sep-Oct;4(5):459-64 [10027596.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):51-4 [10502425.001]
  • [Cites] Fertil Steril. 2000 Apr;73(4):788-98 [10731542.001]
  • [Cites] Mol Hum Reprod. 1998 Dec;4(12):1089-98 [9872358.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:4 [14711375.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):160-7 [15043304.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):325-36 [1700970.001]
  • [Cites] Am J Surg Pathol. 1986 Aug;10(8):568-76 [2426982.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(2):112-22 [3294194.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):151-7 [7048944.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • (PMID = 16409624.001).
  • [ISSN] 1472-6890
  • [Journal-full-title] BMC clinical pathology
  • [ISO-abbreviation] BMC Clin Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1382242
  •  go-up   go-down


98. Uchida K, Oga A, Mano T, Nagatsuka H, Ueyama Y, Sasaki K: Screening for DNA copy number aberrations in mucinous adenocarcinoma arising from the minor salivary gland: two case reports. Cancer Genet Cytogenet; 2010 Dec;203(2):324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for DNA copy number aberrations in mucinous adenocarcinoma arising from the minor salivary gland: two case reports.
  • Mucinous adenocarcinoma (MAC) is a rare malignancy in the minor salivary gland.
  • To identify DNA copy number aberrations, we applied comparative genomic hybridization (CGH) to four samples of MAC in minor salivary gland derived from two patients: a primary tumor and two cervical metastatic lymph nodes from one patient, and a primary tumor from the other patient.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Dosage. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21156253.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


99. Chung TS, Chang HJ, Jung KH, Park SY, Lim SB, Choi HS, Jeong SY: Role of surgery in the treatment of ovarian metastases from colorectal cancer. J Surg Oncol; 2009 Dec 1;100(7):570-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic type of the primary CRC was adenocarcinoma in 26 patients (76.5%), mucinous carcinoma in 7 (20.6%), and signet ring cell carcinoma in 1 (2.9%).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / secondary. Carcinoma, Signet Ring Cell / surgery. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Proportional Hazards Models. Retrospective Studies. Survival Rate


100. Smith AK, Hansel DE, Jones JS: Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. Urology; 2008 May;71(5):915-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma.
  • OBJECTIVES: Cystitis cystica et glandularis (CCEG) and intestinal metaplasia (IM) have been suggested to represent precursors of bladder adenocarcinoma.
  • The relationship between these entities and the subsequent development of bladder carcinoma remains unclear.
  • METHODS: We retrospectively evaluated the association among florid CCEG, IM, and bladder carcinoma.
  • The records and imaging findings of patients with a pathologic diagnosis of florid CCEG and/or IM were reviewed for a concurrent or future diagnosis of bladder carcinoma or pelvic lipomatosis.
  • Of the 117 patients with CCEG, a subset was identified with concurrent mucinous adenocarcinoma (n = 1; <1%), squamous cell carcinoma (n = 4; 3%), or urothelial carcinoma (n = 34; 29%) at diagnosis.
  • Pure IM was identified concurrently with adenocarcinoma in 2 (10%), urothelial carcinoma in 4 (21%), and urothelial carcinoma with glandular differentiation in 1 (5%) of 19 patients.
  • Only 1 new case of urothelial carcinoma was identified after 3 months in 1 patient with CCEG.
  • CONCLUSIONS: Both florid CCEG and IM can be identified in benign bladder specimens or in conjunction with bladder carcinoma.
  • Although IM can be associated with a concurrent diagnosis of carcinoma, we found no evidence that it increases the future risk of malignancy and our findings do not support a recommendation for surveillance cystoscopy in such patients.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455631.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement